

**AMERICAN VIETNAMESE BIOTECH INC**  
**INTERIM CONSOLIDATED FINANCIAL STATEMENTS**

**for the six-month period of the financial year ending December 31, 2025 have been reviewed by**

**NHAN TAM VIET AUDITING COMPANY LIMITED**

## TABLE OF CONTENTS

<b>Content</b>	<b>Page</b>
<b>Statement of The Board of Management</b>	<b>2-4</b>
<b>Independent Auditors' Report</b>	<b>5-7</b>
<b>Audited Interim Consolidated Financial Statements</b>	<b>8-60</b>
<i>Interim Consolidated Balance sheet as at 30 June 2025</i>	<i>8-11</i>
<i>Interim Consolidated Income statement for the six-month period of the financial year ending 31 December 2025</i>	<i>12</i>
<i>Interim Consolidated Cash flows statement for the six-month period of the financial year ending 31 December 2025</i>	<i>13-14</i>
<i>Notes to the Interim consolidated financial statements for the six-month period of the financial year ending 31 December 2025</i>	<i>15-60</i>

## **AMERICAN VIETNAMESE BIOTECH INC**

### **STATEMENT OF THE BOARD OF MANAGEMENT**

The Boards of Management of American Vietnamese Biotech Incorporation (hereinafter referred to as "the Company") present our report together with the interim consolidated financial statements for the six-month period of the financial year ending 31 December 2025, which have been reviewed..

#### **General information about the Company**

American Vietnamese Biotech Incorporation was established under Business Registration Certificate No. 3800237998 issued by the Ho Chi Minh City Department of Planning and Investment on 26 August 2002. During its operation, the Company has amended its business registration certificate 24 times. The 24rd amended Business Registration Certificate for the Joint Stock Company was issued on 17 August 2025.

*The charter capital as stipulated in the 24<sup>th</sup> Enterprise Registration Certificate: VND 1,311,056,500,000.  
Charter capital contributed as at 30 June 2025: VND 1,311,056,500,000.*

#### **Head office:**

Address : 4th Floor, Phu Ma Duong Building, No. 85 Hoang Van Thai Street, Tan Phu Ward, Ho Chi Minh City, Vietnam.  
Telephone : 0651.3.889034  
Fax : 0651.3.889032  
Tax code : 3 8 0 0 2 3 7 9 9 8

#### **Financial Position and Business Operations**

The interim consolidated financial position as at June 30, 2025, the interim consolidated results of operations and the interim consolidated cash flows for the six-month period of the financial year ending December 31, 2025 of the Company are presented in the accompanying interim consolidated financial statements (from page 08 to page 60) attached to this report..

#### **Events occurring during and after the reporting period**

- American Vietnamese Biotech INC ("AMV") with many years of experience in the medical field: providing machinery and equipment systems, supplying consumables,... Facing the increasing demand for health care services, cancer screening and home health care, learning from the infusion center model - built and operated according to Japan's international safety standards - specializing in providing drug, vitamin, protein, therapy and water infusion services to improve patient health, is gradually becoming a popular trend in many countries such as Japan, the US, Thailand. However, in Vietnam, this model is still quite new and has not been widely deployed. At the same time, after reviewing and evaluating the overall mobile examination vehicle project, investment project, joint venture linking medical image archiving and transmission systems (PACS system) with hospitals that the company previously pursued, it did not meet expectations as expected. Therefore, the company boldly divested all or part of those projects, the Company has determined a strategy to strongly develop the clinic and infusion center model in the coming time. This business strategy was approved at the 2024 Annual General Meeting of Shareholders. At present, the Company is continuing to carry out the necessary procedures to put into operation a chain of clinics across 34 provinces and cities nationwide, with the expectation of providing early and reliable diagnostic testing at the most cost-effective level through its network of testing centers.

- Resolution of the Board of Directors No. 0601/2025/NQ-HĐQT dated January 6, 2025 and Resolution of the Board of Directors No. 1701/2025/NQ-HĐQT dated January 17, 2025 on receiving the transfer of VND 204,227,000,000 of contributed capital at Phu Tho Provincial General Hospital, from Sara Vietnam Joint Stock Company. The transfer value from Sara Vietnam Joint Stock Company under contract No. 01/2025/HĐCN/SARA-VIETMY dated February 15, 2025 is VND 204,227,000,000. Up to now, the Company has paid the entire amount of VND 204,227,000,000. However, according to Resolution of the Board of Directors No. 1604/2025/NQ-HĐQT dated April 16, 2025, the Company decided to withdraw capital early from Phu Tho Provincial General Hospital, the capital withdrawal plan is from 2025 to 2028. Up to now, the Hospital has transferred 17,5 billion to the company.



**AMERICAN VIETNAMESE BIOTECH INCO**  
STATEMENT OF THE BOARD OF MANAGEMENT (continue)

In addition to the above events, the Company's Management confirms that no other events have occurred up to the date of this report that require adjustments to the figures or disclosures in the interim consolidated financial statements.

**THE BOARD OF DIRECTORS AND THE BOARD OF MANAGEMENT**

The members of the Board of Directors, the Board of Supervisory Committee and the Board of Management during the period and at the date of this report are:

***The Board of Directors***

Name	Position	Appointed/ Removed
Mr. Nakatani Yoshitaka	Chairman	
Ms. Dang Nhi Nuong	Member	
Mr. Le Khanh Nguyen	Member	

***The Board of Supervisory Committee***

Name	Position	Appointed/ Removed
Ms. Le Thi Huong	Head of Supervisory Committee	
Ms. Nguyen Huong Giang	Member	
Mr. Le Huu Tri	Member	Appointed on July 29, 2025
Ms. Vu Thu Thuy	Member	Dismissed on July 29, 2025

***Board of Management***

Name	Position	Appointed/ Removed
Ms. Dang Nhi Nuong	Director	

***Chief Accountant***

Name	Appointed/ Removed
Ms. Dang Thi Thanh Tuyen	
Ms. Le Thi Viet Ha	Dismissed on June 11, 2025

**Auditor**

Nhan Tam Viet Auditing Company Limited has conducted a review of the interim consolidated financial statements for the six-month period of the financial year ending 31 December 2025.

**The Board of Management's Statement of responsibility**

The Board of Management of the Company is responsible for preparing the interim consolidated financial statements of each year, which give a true and fair view of the interim consolidated financial position of the the Comany and of its interim consolidated operation results and interim consolidated cash flows for the year. In preparing those interim consolidated financial statements, the Board of Management is required to:

- Design and implement an effective internal control system for the purpose of properly preparing and presenting the interim consolidated financial statements so as to minimise errors and frauds;
- Select suitable accounting policies and then apply them consistently;
- Make judgments and estimates that are reasonable and prudent;
- Clearly state whether the applied accounting standards have been complied with, and disclose and explain any material departures that require disclosure in the interim consolidated financial statements;



## AMERICAN VIETNAMESE BIOTECH INCO

### STATEMENT OF THE BOARD OF MANAGEMENT (continue)

- Prepare and present the interim consolidated financial statements in accordance with the applicable Accounting Standards, the Vietnamese Enterprise Accounting Regime, and relevant legal regulations relating to the preparation and presentation of interim consolidated financial statements;
- Prepare the interim consolidated financial statements on the going concern basis unless it is inappropriate to presume that the Company will continue in business

The Board of Management is responsible for ensuring that proper accounting records are kept, which disclose, with reasonable accuracy at any time, the financial position of the Company and to ensure that the consolidated financial statements comply with current regulations of the State. It is also responsible for safeguarding the assets of the Company and hence for taking reasonable steps for the prevention and detection of frauds and other irregularities.

The Board of Management hereby state that the interim consolidated financial statements give a true and fair view of, in all material respects, the interim consolidated financial position of the Company as at 30 June 2025 and of the interim consolidated results of its operation and interim consolidated cash flows the six-month period of the financial year ending 31 December 2025 in accordance with Vietnamese Accounting Standards, Corporate Accounting System and legal regulations relating to preparation and presentation of interim consolidated financial statements

#### Other Commitments

Due to certain objective reasons, the Company failed to fulfill its obligation to disclose the audited financial statements for 2024 within the prescribed deadline. Consequently, the Company's shares were suspended from trading under Decision No. 153/QĐ-SGDHN dated March 17, 2025 of the Hanoi Stock Exchange. The Company has subsequently complied with its disclosure obligations by publishing the audited financial statements for 2024. On June 2, 2025, the Company's shares were reclassified to restricted trading status under Decision No. 681/QĐ-SGDHN due to late submission of the report, and further placed under control status under Decision No. 682/QĐ-SGDHN dated June 2, 2025 as the auditor issued a qualified opinion on the consolidated financial statements for 2023 and 2024. The Company is committed to fully complying with disclosure obligations within the statutory deadlines and implementing measures to remedy the above situation.

In addition to the above issue, the Board of Directors commits that the Company complies with Decree 155/2020/ND-CP dated December 31, 2020 guiding corporate governance applicable to public companies and the Company does not violate the obligation to disclose information as prescribed in Circular No. 96/2020/TT-BTC dated November 16, 2020 of the Ministry of Finance guiding information disclosure on the stock market.

Ho Chi Minh, 28 August 2025

For and on behalf of the Board of Management,

Director



Dang Nhi Nuong

No : 3007.01.02/2025/BCTC-NTV2

**REVIEW REPORT****On the Interim Consolidated Financial Statements  
For the six-month period of the financial year ending 31 December 2025****To : The Shareholders, the Board of Directors and the Board of Management  
American Vietnamese Biotech Incorporation**

We have reviewed the accompanying interim consolidated financial statements of American Vietnamese Biotech Incorporation, prepared on 28 August 2025, from page 08 to page 60, comprising the interim consolidated balance sheet as at 30 June 2025, the interim consolidated statement of profit or loss, the interim consolidated statement of cash flows for the six-month period of the financial year ending 31 December 2025, and the notes to the interim consolidated financial statements..

**The Board of Management's responsibility**

The Management of American Vietnamese Biotech Incorporation is responsible for the preparation and fair presentation of the interim consolidated financial statements in accordance with Vietnamese Accounting Standards, Vietnamese Accounting System, and relevant legal regulations relating to the preparation and presentation of interim consolidated financial statements, and for such internal control as the Management determines is necessary to enable the preparation of interim consolidated financial statements that are free from material misstatement, whether due to fraud or error..

**Auditors' responsibility**

Our responsibility is to express a conclusion on the interim financial statements based on our review. We conducted our review in accordance with Vietnamese Standard on Review Engagements (VSRE) 2410 – Review of Interim Financial Information Performed by the Independent Auditor of the Entity.

A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Vietnamese Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

**Basis for Qualified Opinion**

- We were unable to observe the cash count on December 31, 2024, with a cash balance of VND 1,885,137,331, as we had not been appointed as the auditor at that time. Accordingly, we do not express an opinion on the accuracy, existence, and completeness of cash as at that date.

- Certain associates were established but have not yet formed or possess insignificant assets to support their business operations. The capital contributions to these associates amounted to VND 345,181,500,000 (Note V.13). Based on the audit procedures performed, we have not obtained sufficient appropriate audit evidence to assess the reasonableness of these investments or their impact on the interim consolidated financial statements for the six-month period of the financial year ending 31



- As at June 30, 2025, certain advance payments to suppliers amounting to VND 77,700,850,000 had passed the contractual delivery deadlines for goods and services. In addition, certain other advance payments to suppliers amounting to VND 208,603,170,000 had also passed the contractual delivery deadlines, and the parties had subsequently terminated the contracts. As of the date of issuance of these financial statements, the Company has not yet recovered the above amounts. We performed additional audit procedures but were unable to obtain sufficient and appropriate audit evidence to assess the recoverability of these advance payments at the above-mentioned dates. Accordingly, we are unable to express an opinion on the recoverability of these advances as at June 30, 2025, or on the impact of this matter on the accompanying interim consolidated financial statements of the Company.

- As at June 30, 2025, Viet My Medical Investment Joint Stock Company was participating in a joint investment project for a centralized medical waste treatment facility with Sara Vung Tau Joint Stock Company, with an investment amount of VND 61,717,000,000. As of the date of issuance of this report, the project had not yet completed the necessary procedures to commence operations. Based on the audit procedures performed, we were unable to assess the effectiveness and recoverability of this investment or its impact on the interim consolidated financial statements for the six-month period of the financial year ending December 31, 2025.

- The Company has invested in and installed medical equipment and the RIS-PACS medical imaging storage and transmission software system under lease and cooperation contracts with hospitals and medical centers, with total investment costs as at June 30, 2025 amounting to VND 80,256,761,457 (of which VND 59,564,895,987 had been handed over to hospitals for use and VND 20,691,865,470 had not yet been handed over). At certain hospitals, revenue has been generated; however, due to the absence of specific and consistent guidelines on the settlement of diagnostic imaging services based on the PACS system, the Company does not have a reliable basis to fully determine the economic benefits derived from the above leasing and cooperation arrangements. Nevertheless, the Company has recognized depreciation expenses for the portion of assets handed over in its operating results, with accumulated depreciation as at June 30, 2025 of VND 23,783,166,595 (including VND 20,811,796,801 as at December 31, 2024 and VND 2,971,369,794 for the six-month period of 2025). Based on the audit procedures performed, we were unable to determine the impact of these matters on the interim consolidated financial statements for the six-month period of the financial year ending December 31, 2025.

- As at June 30, 2025, the balance of construction in progress for the procurement of machinery and equipment to be operated at clinics amounted to VND 3,862,061,818, which has been outstanding for a long time without being accepted, handed over, and put into use. Based on the audit procedures performed, we were unable to estimate the fair value of this construction in progress or its impact on the interim consolidated financial statements for the six-month period of the financial year ending December 31, 2025.

- As at June 30, 2025, short-term loan receivables amounted to VND 70,808,050,000. Based on the audit procedures performed, we were unable to obtain sufficient appropriate audit evidence to assess the recoverability of these loans as at the above-mentioned date. Accordingly, we are unable to express an opinion on the recoverability of this loan balance as at June 30, 2025 or on the impact of this matter on the accompanying interim consolidated financial statements of the Company



### Qualified Opinion

Based on our review, except for the possible effects of the matters described in the 'Basis for Qualified Opinion' section, nothing has come to our attention that causes us to believe that the accompanying interim consolidated financial statements do not present fairly, in all material respects, the interim consolidated financial position of American Vietnamese Biotech Incorporation as at June 30, 2025, and its interim consolidated results of operations and interim consolidated cash flows for the six-month period of the financial year ending December 31, 2025, in accordance with Vietnamese Accounting Standards, the Vietnamese Accounting System, and the relevant statutory requirements on the preparation and presentation of interim consolidated financial statements.

### Emphasis of Matter

As at June 30, 2025, the Company's loan from Viet Capital Commercial Joint Stock Bank amounted to VND 23,126,095,827 and was overdue for repayment. As of the date of issuance of this report, the loan remained overdue. The request for loan extension was submitted by the Company under Official Letter No. 05/2024/CV-AMV in October 2024 and was approved by Viet Capital Commercial Joint Stock Bank under Official Letter No. 212/2024/BVbank/CV-QL&THN dated April 9, 2024. However, as of the reporting date, the Company had not fully settled the outstanding principal and is continuing to work with the Bank to request an extension of the loan. (Refer to Note V.18a).

Hanoi, 28 August 2025

**NHAN TAM VIET AUDITING COMPANY LIMITED**

**Deputy General Director**



**Nguyen Van Tan**

Audit Practice Registration Certificate

No. 5348-2025-124-1

**AMERICAN VIETNAMESE BIOTECH INCORPORATION**

Address: 4th Floor, Phu Ma Duong Building, No. 85 Hoang Van Thai Street, Tan My Ward, Ho Chi Minh City, Vietnam  
**INTERIM CONSOLIDATED FINANCIAL STATEMENTS**

For the six-month period of the financial year ending 31 December 2025

**INTERIM BALANCE SHEET**

As at 30 June 2025

Unit: VND

ASSETS	Code	Note	Ending balance	Beginning balance
<b>A - CURRENT ASSETS</b>	<b>100</b>		<b>662,137,836,191</b>	<b>951,892,884,765</b>
<b>I. Cash and cash equivalents</b>	<b>110</b>	<b>V.1</b>	<b>13,152,760,376</b>	<b>16,194,180,757</b>
1. Cash	111		13,152,760,376	16,194,180,757
2. Cash equivalents	112		-	-
<b>II. Short-term financial investments</b>	<b>120</b>		<b>98,300,000</b>	<b>98,300,000</b>
1. Trading securities	121		-	-
2. Provision for impairment of trading securities	122		-	-
3. Held-to-maturity investments	123	V.2	98,300,000	98,300,000
<b>III. Short-term receivables</b>	<b>130</b>		<b>576,980,319,210</b>	<b>882,737,142,898</b>
1. Short-term trade receivables	131	V.3	141,399,752,110	297,129,219,082
2. Short-term advances to suppliers	132	V.4	83,981,479,039	540,213,205,047
3. Short-term inter-company receivables	133		-	-
4. Receivables from construction contracts under perce	134		-	-
5. Short-term loan receivables	135	V.5	70,808,050,000	62,850,000,000
6. Other short-term receivables	136	V.6a	330,833,326,265	4,938,740,977
7. Provision for short-term doubtful debts	137	V.7	(50,042,288,204)	(22,394,022,208)
8. Deficits in assets awaiting solution	139		-	-
<b>IV. Inventories</b>	<b>140</b>		<b>67,720,793,911</b>	<b>49,084,052,777</b>
1. Inventories	141	V.8	67,720,793,911	49,084,052,777
2. Provisions for devaluation of inventories	149		-	-
<b>V. Other short-term assets</b>	<b>150</b>		<b>4,185,662,694</b>	<b>3,779,208,333</b>
1. Short-term prepayments	151	V.9a	111,806,713	182,379,162
2. Value added tax deductibles	152		4,069,967,091	3,390,708,424
3. Taxes and other receivables from the State budget	153	V.15	3,888,890	206,120,747
4. Government bond sale and repurchase transactions	154		-	-
5. Other short-term assets	155		-	-

**AMERICAN VIETNAMESE BIOTECH INCORPORATION**

Address: 4th Floor, Phu Ma Duong Building, No. 85 Hoang Van Thai Street, Tan My Ward, Ho Chi Minh City, Vietnam

**INTERIM CONSOLIDATED FINANCIAL STATEMENTS**

For the six-month period of the financial year ending 31 December 2025

**Interim Consolidated Balance Sheet (continued)**

ASSETS	Code	Note	Ending balance	Beginning balance
<b>B - NON-CURRENT ASSETS</b>	<b>200</b>		<b>1,254,484,658,770</b>	<b>1,003,747,749,992</b>
<b>I. Long-term receivables</b>	<b>210</b>		<b>211,142,000,000</b>	<b>61,988,000,000</b>
1. Long-term trade receivables	211		-	-
2. Long-term advances to suppliers	212		-	-
3. Operating capital contributed to dependent units	213		-	-
4. Long-term inter-company receivables	214		-	-
5. Long-term loans receivable	215		-	-
6. Other long-term receivables	216	V.6b	211,142,000,000	61,988,000,000
7. Provision for long-term doubtful debts	219		-	-
<b>II. Fixed assets</b>	<b>220</b>		<b>276,508,665,020</b>	<b>289,495,044,522</b>
1. Tangible fixed assets	221	V.10	160,047,861,668	166,973,346,352
Cost	222		223,883,246,202	220,205,446,202
Accumulated depreciation	223		(63,835,384,534)	(53,232,099,850)
2. Finance lease assets	224		-	-
Cost	225		-	-
Accumulated depreciation	226		-	-
3. Intangible assets	227	V.11	116,460,803,352	122,521,698,170
Cost	228		148,700,446,337	149,316,480,623
Accumulated amortisation	229		(32,239,642,985)	(26,794,782,453)
<b>III. Investment property</b>	<b>230</b>		-	-
Cost	231		-	-
Accumulated depreciation	232		-	-
<b>IV. Long-term assets in progress</b>	<b>240</b>	<b>V.12</b>	<b>28,722,290,646</b>	<b>27,466,646,084</b>
1. Long-term work in progress	241		-	-
2. Construction in progress	242		28,722,290,646	27,466,646,084
<b>V. Long-term financial investments</b>	<b>250</b>	<b>V.13</b>	<b>734,938,191,325</b>	<b>621,833,841,759</b>
1. Investments in subsidiaries	251		-	-
2. Investments in joint-ventures, associates	252		720,324,855,375	621,833,841,759
3. Equity investments in other entities	253		14,658,000,000	-
4. Provision for impairment of long-term financial inve	254		(44,664,050)	-
5. Held-to-maturity investments	255		-	-
<b>VI. Other long-term assets</b>	<b>260</b>		<b>3,173,511,779</b>	<b>2,964,217,627</b>
1. Long-term prepayments	261	V.9b	2,762,483,528	2,524,341,047
2. Deferred tax assets	262		-	-
3. Long-term reserved spare parts	263		-	-
4. Other long-term assets	268		-	-
5. Goodwill	269		411,028,251	439,876,580
<b>TOTAL ASSETS</b>	<b>270</b>		<b>1,916,622,494,961</b>	<b>1,955,640,634,757</b>



**AMERICAN VIETNAMESE BIOTECH INCORPORATION**

Address: 4th Floor, Phu Ma Duong Building, No. 85 Hoang Van Thai Street, Tan My Ward, Ho Chi Minh City, Vietnam

**INTERIM CONSOLIDATED FINANCIAL STATEMENTS**

For the six-month period of the financial year ending 31 December 2025

**Interim Consolidated Balance Sheet (continued)**

RESOURCES	Code	Note	Ending balance	Beginning balance
<b>C - LIABILITIES</b>	<b>300</b>		<b>285,857,380,683</b>	<b>282,930,824,433</b>
<b>I. Current liabilities</b>	<b>310</b>		<b>285,519,582,400</b>	<b>156,093,026,150</b>
1. Short-term trade payables	311	V.14	25,279,812,907	15,246,276,978
2. Short-term advances from customers	312		-	50,000,000
3. Taxes and amounts payable to the State budget	313	V.15	2,568,539,958	3,138,536,295
4. Payables to employees	314		2,484,598,021	1,669,658,432
5. Short-term accrued expenses	315	V.16a	28,692,463,604	29,744,676,641
6. Short-term inter-company payables	316		-	-
7. Payables relating to construction contracts under per	317		-	-
8. Short-term unearned revenue	318		-	-
9. Other short-term payables	319	V.17	76,821,080,861	78,118,781,977
10. Short-term loans and obligations under finance lease	320	V.18a	149,673,087,049	28,125,095,827
11. Short-term provisions	321		-	-
12. Bonus and welfare funds	322		-	-
13. Price stabilization fund	323		-	-
14. Government bond sale and repurchase transactions	324		-	-
<b>II. Long-term liabilities</b>	<b>330</b>		<b>337,798,283</b>	<b>126,837,798,283</b>
1. Long-term trade payables	331		-	-
2. Long-term advances from customers	332		-	-
3. Long-term accrued expenses	333	V.16b	337,798,283	337,798,283
4. Inter-company payables regarding operating capital	334		-	-
5. Long-term inter-company payables	335		-	-
6. Long-term unearned revenue	336		-	-
7. Other long-term payables	337		-	-
8. Long-term loans and obligations under finance lease	338	V.18b	-	126,500,000,000
9. Convertible bonds	339		-	-
10. Preference shares	340		-	-
11. Deferred tax liabilities	341		-	-
12. Long-term provisions	342		-	-
13. Scientific and technological development fund	343		-	-

**AMERICAN VIETNAMESE BIOTECH INCORPORATION**

Address: 4th Floor, Phu Ma Duong Building, No. 85 Hoang Van Thai Street, Tan My Ward, Ho Chi Minh City, Vietnam

**INTERIM CONSOLIDATED FINANCIAL STATEMENTS**

For the six-month period of the financial year ending 31 December 2025

**Interim Consolidated Balance Sheet (continued)**

RESOURCES	Code	Note	Ending balance	Beginning balance
<b>D - OWNERS' EQUITY</b>	<b>400</b>		<b>1,630,765,114,278</b>	<b>1,672,709,810,324</b>
<b>I. Owners's equity</b>	<b>410</b>	<b>V.19</b>	<b>1,630,765,114,278</b>	<b>1,672,709,810,324</b>
1. Paid-in capital	411		1,311,056,500,000	1,311,056,500,000
- Ordinary shares carrying voting rights	411a		1,311,056,500,000	1,311,056,500,000
- Preference shares	411b		-	-
2. Share premium	412		(395,300,000)	(395,300,000)
3. Convertible options	413		-	-
4. Other owner's capital	414		-	-
5. Treasury shares	415		-	-
6. Assets revaluation reserve	416		-	-
7. Foreign exchange reserve	417		-	-
8. Investment and development fund	418		-	-
9. Enterprise reorganisation support fund	419		-	-
10. Other reserves	420		-	-
11. Retained earnings	421		252,107,189,514	291,829,173,766
- Retained earnings Accumulated to the prior year en	421a		291,829,173,766	302,973,394,409
- Retained earnings of the current year	421b		(39,721,984,252)	(11,144,220,643)
12. Construction investment fund	422		-	-
13. Non-controlling Interests (NCI)	429		67,996,724,764	70,219,436,558
<b>II. Other resources and funds</b>	<b>430</b>		-	-
1. Subsidised funds	431		-	-
2. Funds for fixed assets acquisition	432		-	-
<b>TOTAL RESOURCES</b>	<b>440</b>		<b>1,916,622,494,961</b>	<b>1,955,640,634,757</b>

Prepared by

  
 Nguyen Thu Huyen

Chief Accountant

  
 Dang Thi Thanh Tuyen

Prepared on 28 August 2025

President


  
 Dang Nhi Nuong



**AMERICAN VIETNAMESE BIOTECH INCORPORATION**

Address: 4th Floor, Phu Ma Duong Building, No. 85 Hoang Van Thai Street, Tan My Ward, Ho Chi Minh City, Vietnam

**INTERIM CONSOLIDATED FINANCIAL STATEMENTS**

For the six-month period of the financial year ending 31 December 2025

**INTERIM INCOME STATEMENT**

For the six-month period of the financial year ending 31 December 2025

Unit: VND

Cumulative from the beginning of the year  
to the end of this period

ITEMS	Code	Note	Current period	Previous period
1. Revenue from sales of goods and rendering of servi	01	VI.1	102,051,725,225	81,408,192,173
2. Revenue deductions	02		-	-
3. Net revenue from goods sold and services rendered	10		102,051,725,225	81,408,192,173
4. Cost of sales	11	VI.2	86,256,150,530	74,949,925,060
5. Gross profit from goods sold and services rendered	20		15,795,574,695	6,458,267,113
6. Financial income	21	VI.3	1,423,192,902	1,060,001,096
7. Financial expenses	22	VI.4	9,289,043,525	10,059,513,999
In which: interest expenses	23		9,244,379,475	10,016,576,291
8. Share of profit or loss of associates and joint ventur	24		(2,628,486,384)	(14,656)
9. Selling expenses	25	VI.5	281,472,526	(1,353,755,293)
10. General and administration expenses	26	VI.6	38,792,384,220	17,822,890,312
11. Net profit from operating activities	30		(33,772,619,058)	(19,010,395,465)
12. Other income	31	VI.7	163,110,229	1,946,297,117
13. Other expenses	32	VI.8	7,054,311,084	153,683,692
14. Profit from other activities	40		(6,891,200,855)	1,792,613,425
15. Accounting profit before tax	50		(40,663,819,913)	(17,217,782,040)
16. Current corporate income tax expense	51	VI.9	342,276,614	429,277,098
17. Deferred corporate income tax expense	52		-	-
18. Net profit after corporate income tax	60		(41,006,096,527)	(17,647,059,138)
19. Profit after tax attributable to owners of the parent	61		(39,721,984,252)	(16,730,798,237)
20. Profit after tax attributable to non-controlling inter	62		(1,284,112,275)	(916,260,901)
21. Basic earnings per share	70	VI.10	(303)	(128)
22. Diluted earnings per share	71	VI.10	(303)	(128)

Prepared by



Nguyen Thu Huyen

Chief Accountant



Dang Thi Thanh Tuyen

Prepared on 28 August 2025



President

Dang Nhi Nuong



**AMERICAN VIETNAMESE BIOTECH INCORPORATION**

Address: 4th Floor, Phu Ma Duong Building, No. 85 Hoang Van Thai Street, Tan My Ward, Ho Chi Minh City, Vietnam  
**INTERIM CONSOLIDATED FINANCIAL STATEMENTS**

For the six-month period of the financial year ending 31 December 2025

**INTERIM CASH FLOW STATEMENT**

(Under indirect method)

For the six-month period of the financial year ending 31 December 2025

Unit: VND

ITEMS	Code	Note	Cumulative from the beginning of the year to the end of this period	
			Current period	Previous period
<b>I. Cash flows from operating activities</b>				
1. Profit before tax	01		(40,663,819,913)	(17,217,782,040)
2. Adjustments for:				
- Depreciation of fixed assets and investment properties	02		16,900,945,536	10,660,383,426
- Provisions	03		27,692,930,046	10,872,153,269
- Exchange gains, losses arising from revaluation of monetary items denominated in foreign currency	04		-	-
- Profits, losses from investing activities	05		(1,563,192,902)	(380,114,973)
- Interest expenses	06		9,244,379,475	10,016,576,291
- Other adjustments	07		-	-
3. Operating income before changes in working capital	08		11,611,242,242	13,951,215,973
- Increase, decrease in receivables	09		311,448,621,350	29,772,944,804
- Increase, decrease in inventories	10		(18,636,741,134)	83,038,225,058
- Increase, decrease in payables	11		2,836,018,678	(3,591,335,944)
- Increase, decrease in prepaid expenses	12		(179,153,604)	150,006,508
- Increase, decrease in trading securities	13		-	-
- Interest paid	14		(8,066,756,165)	(7,508,147,670)
- Corporate income tax paid	15		-	(52,302,646)
- Other proceeds from operating activities	16		-	-
- Other payments for operating activities	17		-	-
Net cash flows from operating activities	20		299,013,231,367	115,760,606,083
<b>II. Cash flows from investing activities</b>				
1. Payment for purchases or construction of fixed assets and other long - term assets	21		(1,493,644,562)	(41,696,005,030)
2. Proceeds from disposal of fixed assets and other long - term assets	22		-	-
3. Loans to and payments for purchase of debt instruments of other entities	23		(23,611,000,000)	(30,500,000,000)
4. Collections from borrowers and proceeds from disposal of debt instruments of other entities	24		7,023,950,000	45,014,465,760
5. Payments for investments in other entities	25		(320,004,500,000)	(97,163,500,000)
6. Proceeds from disposal of investments in other entities	26		40,533,658,509	-
7. Interests and dividends received	27		448,893,083	380,114,973
Net cash flows from investing activities	30		(297,102,642,970)	(123,964,924,297)

**AMERICAN VIETNAMESE BIOTECH INCORPORATION**

Address: 4th Floor, Phu Ma Duong Building, No. 85 Hoang Van Thai Street, Tan My Ward, Ho Chi Minh City, Vietnam

**INTERIM CONSOLIDATED FINANCIAL STATEMENTS**

For the six-month period of the financial year ending 31 December 2025

**Interim Consolidated Statement of Cash Flows (continued)**

ITEMS	Code	Note	Cumulative from the beginning of the year to the end of this period	
			Current period	Previous period
III. Cash flows from financial activities				
1. Gains from stock issuance and capital contributions from shareholders	31		-	-
2. Repayments of capital contributions to owners and re-purchase of stocks already issued	32		-	-
3. Receipts from loans	33		46,991,222	3,790,000,000
4. Payment of loan principal	34		(4,999,000,000)	(14,153,437,823)
5. Dividends and profit shared to the owners	35		-	-
6. Dividends and profit paid to the owners	36		-	-
Net cash flows from financial activities	40		(4,952,008,778)	(10,363,437,823)
Net cash flows during the year	50		(3,041,420,381)	(18,567,756,037)
Beginning cash and cash equivalents	60	V.1	16,194,180,757	38,838,831,967
Effects of fluctuations in foreign exchange rates	61		-	-
Ending cash and cash equivalents	70	V.1	13,152,760,376	20,271,075,930

Prepared by



Nguyen Thu Huyen

Chief Accountant



Dang Thi Thanh Tuyen

Prepared on 28 August 2025

President



Dang Nhi Nuong



**AMERICAN VIETNAMESE BIOTECH INCORPORATION**

Address: 4th Floor, Phu Ma Duong Building, No. 85 Hoang Van Thai Street, Tan My Ward, Ho Chi Minh City, Vietnam

For the six-month period of the financial year ending 31 December 2025

**NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS**

**For the six-month period of the financial year ending 31 December 2025**

**I. OPERATION FEATURES**

1. **Ownership form** : Joint Stock Company
2. **Business Sector** : Medical equipment and medical testing chemicals

**3. General information about the Company**

American Vietnamese Biotech Incorporation was established under Business Registration Certificate No. 3800237998 issued by the Ho Chi Minh City Department of Planning and Investment on 26 August 2002. During its operation, the Company has amended its business registration certificate 24 times. The 24rd amended Business Registration Certificate for the Joint Stock Company was issued on 17 August 2025.

*The charter capital as stipulated in the 24<sup>rd</sup> Enterprise Registration Certificate: VND 1,311,056,500,000.*

*Charter capital contributed as at 30 June 2025: VND 1,311,056,500,000.*

**Head office:**

Address : 4th Floor, Phu Ma Duong Building, No. 85 Hoang Van Thai Street, Tan Phu Ward, District 7, Ho Chi Minh City, Vietnam.

Telephone : 0651.3.889034

Fax : 0651.3.889032

Tax code : 3 8 0 0 2 3 7 9 9 8

**4. Business sector :**

- Retail of medicines, medical equipment, cosmetics and hygiene products in specialized stores (Details: pharmaceutical business, buying and selling medical equipment, medical testing tools and chemicals);
  - Manufacture of medical, dental, orthopedic and rehabilitation equipment and instruments (Details: Manufacturing medical testing equipment);
  - Production of drugs, pharmaceutical chemicals and medicinal materials (Details: Production and trading of vaccines and medical biological products);
  - Production of cosmetics, soaps, detergents, polishes and cleaning products; Agents, brokers, auctioneers (Details: Agents for consignment of goods, production of plastic products);
  - Real estate business, land use rights owned, used or rented (Details: Real estate business);
  - Water exploitation, treatment and supply; Drainage and wastewater treatment; Scrap recycling; Pollution treatment and other waste management activities;
  - Other professional, scientific and technological activities not elsewhere classified (Details: Technology transfer);
  - Other business lines specifically specified in the Business Registration Certificate./.
- Main business activities: Trading in medical equipment and medical testing chemicals.

**5. Normal production and business cycle**

Normal business production cyclecompany no more than 12 months



**AMERICAN VIETNAMESE BIOTECH INCORPORATION**

Address: 4th Floor, Phu Ma Duong Building, No. 85 Hoang Van Thai Street, Tan My Ward, Ho Chi Minh City, Vietnam

For the six-month period of the financial year ending 31 December 2025

**Notes to the Interim Consolidated Financial Statements (continued)****6. Statement of Comparability of Information in the Consolidated Financial Statements**

The figures in the interim consolidated financial statements for the six-month period of the financial year ending 31 December 2025 are entirely consistent and comparable with those in the interim consolidated financial statements for the six-month period of the financial year ending 31 December 2024 and the consolidated financial statements for the financial year ended 31 December 2024..

**7. Employees**

As at the end of the reporting period, the Company had 113 employees (compared to 103 employees at the beginning of the year).

**8. Business structure: .  
a, Subsidiary**

Company name	Head office Totalress	Owner ship ratio	Voting ratio	Main business lines
Viet My Hospital Investment Joint Stock Company	307 Nguyen Du Street, Nong Trang Ward, Viet Tri City, Phu Tho Province, Vietnam	83.33%	83.33%	Wholesale of pharmaceuticals and medical supplies; sale of medical equipment
Ha Long Kyoto Technology Development Joint Stock Company	Lot A15, Cuong Thinh Industrial Park, Ba Che Commune, Son Xa District, Quang Ninh Province, Vietnam	99.00%	99.00%	Production of pharmaceuticals, infusion solutions, and infusion bottles
Bai Chay Kyoto Clinic Joint Stock Company	Lot 4, Quang Trung Ward, Ha Long City, Quang Ninh Province, Vietnam	98.00%	98.00%	General clinic, specialized clinic
Song Hau New Technology Application Research Joint Stock Company	Song Hau Industrial Park, Chau Thanh District, Can Tho City, Vietnam	98.00%	98.00%	Production of infusion solutions, infusion bottles, and infusion caps
Ha Dong Clinic Joint Stock Company	Floor 3, No. 1 Phuc Thinh Building, Kien Hung Ward, Ha Dong District, Hanoi, Vietnam	98.00%	98.00%	General, specialist and dental clinics
Hoa Binh Clinic Joint Stock Company	Floor 1, No. 83, Chinh Lu Street, Group 13, Hoa Binh City, Hoa Binh Province, Vietnam	98.00%	98.00%	General, specialist and dental clinics
Viet Tri Clinic Joint Stock Company	307 Nguyen Du Street, Nong Trang Ward, Viet Tri City, Phu Tho Province, Vietnam	98.00%	98.00%	General, specialist and dental clinics
Gia Lam High-Tech Clinic Joint Stock Company	No. 18, Phap Van – Tu Hiep Urban Area, Yen So Ward, Hoang Mai District, Hanoi, Vietnam	98.00%	98.00%	General, specialist and dental clinics
Can Tho Medicare Clinic Joint Stock Company	No. 408, Van Cu Street, An Binh Ward, Ninh Kieu District, Can Tho City, Vietnam	98.00%	98.00%	General, specialist and dental clinics
Hau Giang Medicare Clinic Joint Stock Company	No. 16, Lane 1, Residential Area 4, Vi Thanh Ward, Hau Giang Province, Vietnam	98.00%	98.00%	General, specialist and dental clinics
Soc Trang Medicare Clinic Joint Stock Company	No. 438, Le Duan Street, Phu Loi Ward, Soc Trang City, Vietnam	98.00%	98.00%	General, specialist and dental clinics
Nga Bay Medicare Clinic	No. 622, 30/4 Street, Quarter 5,	98.00%	98.00%	General, specialist and

**AMERICAN VIETNAMESE BIOTECH INCORPORATION**

Address: 4th Floor, Phu Ma Duong Building, No. 85 Hoang Van Thai Street, Tan My Ward, Ho Chi Minh City, Vietnam

For the six-month period of the financial year ending 31 December 2025

**Notes to the Interim Consolidated Financial Statements (continued)**

Joint Stock Company	Nga Bay Ward, Nga Bay Town, Hau Giang Province, Vietnam				dental clinics
Leopard Solutions Joint Stock Company	No. 79, Ap Dinh, Dinh An Commune, Cu Chi District, Ho Chi Minh City, Vietnam	75.00%	75.00%		Computer programming
Vietnam National Software Production Joint Stock Company (VN Soft) (*)	No. 36, Phap Van – Tu Hiep Urban Area, Hoang Liet Ward, Hoang Mai District, Hanoi, Vietnam	98.00%	98.00%		Computer programming

(\*) The Board of Directors' Resolution No. 2502.01/2025/NQ-BOD dated February 25, 2025 on divestment from Vietnam National Software Production Joint Stock Company. As at the date of issuance of this report, the Company has fully divested its capital from this subsidiary.

The remaining subsidiaries are operating under normal business conditions.

**b, Indirectly owned subsidiaries:**

Company name	Head office Totalress	Owners hip ratio	Voting ratio	Main business lines
Famicare Thu Duc Joint stock Company	28 Hien Vuong, Hiep Phu Ward, Thu Duc City, Ho Chi Minh City	96.04%	96.04%	General, specialist and dental clinics
Medicare Nha Be Clinic Joint Stock Company	568 Le Van Luong Hamlet 3, Phuoc Kien Commune. Nha Be District, Ho Chi Minh City	96.04%	96.04%	General, specialist and dental clinics
Famicare Vinh Yen Joint Stock Company	2nd Floor, No. 79 Ba Trieu Street, Lien Bao Ward, Vinh Yen City, Vinh Phuc Province, Vietnam	98,00%	98,00%	General, specialist and dental clinics

**c, Associate company:**

Company name	Head office Totalress	Owne rship ratio	Votin g ratio	Main business lines
Golab Phap Van Diagnostic Center Joint Stock Company	1st Floor, Lot BT 5, No. 18, New Urban Area Phap Van - Tu Hiep, Hoang Liet Ward, Hoang Mai District, Hanoi City, Vietnam	35%	35%	General, Specialized, and Dental Clinic
Famicare Phap Van Joint Stock Company	1st Floor, Lot BT 5, No. 17, New Urban Area Phap Van - Tu Hiep, Hoang Liet Ward, Hoang Mai District, Hanoi City, Vietnam	35%	35%	General, Specialized, and Dental Clinic
Golab Go Vap Diagnostic Center Joint Stock Company	1st Floor, No. 178 Nguyen Thai Son, Ward 4, Go Vap District, Ho Chi Minh City	35%	35%	General, Specialized, and Dental Clinic
Nghe An Polyclinic Joint Stock Company	1st Floor, No. 68 Ho Tong Thoc Street, Block 13, Nghi Phu Ward, Vinh City, Nghe An	35%	35%	General, Specialized, and Dental Clinic
Ba Dinh Polyclinic Joint Stock Company	No. 37A Maternity Slope, De La Thanh Street, Ngoc Khanh Ward, Ba Dinh District, Hanoi City, Vietnam	35%	35%	General, Specialized, and Dental Clinic
Golab Bac Lieu Diagnostic	Ground Floor No. 210, Ba Trieu Street,	35%	35%	General, Specialized,



**AMERICAN VIETNAMESE BIOTECH INCORPORATION**

Address: 4th Floor, Phu Ma Duong Building, No. 85 Hoang Van Thai Street, Tan My Ward, Ho Chi Minh City, Vietnam

For the six-month period of the financial year ending 31 December 2025

**Notes to the Interim Consolidated Financial Statements (continued)**

<b>Company name</b>	<b>Head office Totalress</b>	<b>Own ership ratio</b>	<b>Votin g ratio</b>	<b>Main business lines</b>
Center Joint Stock Company	Ward 3, Bac Lieu City, Bac Lieu Province			and Dental Clinic
Golab Tien Giang Diagnostic Center Joint Stock Company	368A, Phuoc Hoa Hamlet, Phuoc Thanh Commune, My Tho City, Tien Giang Province	35%	35%	General, Specialized, and Dental Clinic
Golab Binh Duong Diagnostic Center Joint Stock Company	634 Binh Duong Avenue, Hiep Thanh Ward, Thu Dau Mot City, Binh Duong Province	35%	35%	General, Specialized, and Dental Clinic
Famicare Tuyen Quang Joint Stock Company	2nd Floor, No. 23, Hoa Lu Street, Group 01, Phan Thiet Ward, Tuyen Quang City, Tuyen Quang Province	35%	35%	General, Specialized, and Dental Clinic
Golab Ha Giang Diagnostic Center Joint Stock Company	1st Floor, No. 75, Nguyen Thai Hoc Street, Group 22, Minh Khai Ward, Ha Giang City, Ha Giang Province, Vietnam	49%	49%	General, Specialized, and Dental Clinic
Huu Nghi Medicare Clinic Joint Stock Company	No. 179 Giai Phong Street, Dong Tam Ward, Hai Ba Trung District, Hanoi City, Vietnam	49%	49%	General, Specialized, and Dental Clinic
Medicare Ninh Binh Polyclinic Joint Stock Company	House No. 128 Tue Tinh Street, Nam Thanh Ward, Ninh Binh City, Ninh Binh Province	49%	49%	General, Specialized, and Dental Clinic
Golab Vung Tau Laboratory Center Joint Stock Company	No. 745 Vo Van Kiet Street, Long Tam Ward, Ba Ria City, Ba Ria - Vung Tau Province, Vietnam	49%	49%	General, Specialized, and Dental Clinic
Famicare Hung Yen Joint Stock Company	2nd Floor, No. 588 Nguyen Van Linh, Hien Nam Ward, Hung Yen City, Hung Yen Province, Vietnam	35%	35%	General, Specialized, and Dental Clinic
Golab Dong Thap Diagnostic Center Joint Stock Company	No. 102 Nguyen Van Tre extended street, Dong Thap Hospital residential area, My Tan commune, Cao Lanh city, Dong Thap province, Vietnam	35%	35%	General, Specialized, and Dental Clinic
Golab Ben Tre Test Center Joint Stock Company	Floor 1, No. 613B4 Ca Van Thinh Street, Phu Khuong Ward, Vinh Long Province, Vietnam	24%	24%	General, Specialized, and Dental Clinic
Golab Kon Tum Diagnostic Center Joint Stock Company	No. 370 Ba Trieu Street, Quang Trung Ward, Kon Tum Town, Kon Tum Province, Vietnam, Vietnam	45%	45%	General, Specialized, and Dental Clinic
Golab District 5 Diagnostic Center Joint Stock Company	26 Tan Thanh, Ward 12, District 5, Ho Chi Minh City	35%	35%	General, Specialized, and Dental Clinic
Golab Quang Ngai Diagnostic Center Joint Stock Company	115 Nguyen Trai, Group 4, Quang Phu Ward, Quang Ngai City, Quang Ngai	35%	35%	General, Specialized, and Dental Clinic
Golab Binh Thuan Test Center Joint Stock Company	Floor 1, No. 92 Tu Van Tu Street, Phan Thiet Ward, Lam Dong Province, Vietnam	23%	23%	General, Specialized, and Dental Clinic
Golab Tay Ninh Diagnostic Center Joint Stock Company	572A 30/4 Street, Quarter 5, Ward 3, Tay Ninh City, Tay Ninh Province, Vietnam	45%	45%	General, Specialized, and Dental Clinic

**AMERICAN VIETNAMESE BIOTECH INCORPORATION**

Address: 4th Floor, Phu Ma Duong Building, No. 85 Hoang Van Thai Street, Tan My Ward, Ho Chi Minh City, Vietnam

For the six-month period of the financial year ending 31 December 2025

**Notes to the Interim Consolidated Financial Statements (continued)**

<b>Company name</b>	<b>Head office Totalress</b>	<b>Owne rship ratio</b>	<b>Votin g ratio</b>	<b>Main business lines</b>
Golab Yen Bai Test Center Joint Stock Company	Floor 1, No. 305 Thanh Cong Street, Yen Bai Ward, Lao Cai Province, Vietnam	25%	25%	General, Specialized, and Dental Clinic
Famicare Quang Binh Joint Stock Company	Cluster 1, Residential Group 14, Dong Hoi Ward, Quang Tri Province, Vietnam	35%	35%	General, Specialized, and Dental Clinic
Golab Hung Yen Diagnostic Center Joint Stock Company	1st Floor, No. 588 Nguyen Van Linh, Hien Nam Ward, Hung Yen City, Hung Yen Province	35%	35%	General, Specialized, and Dental Clinic
Famicare Vinh Phuc Joint Stock Company	Phu Thuong residential group, Lap Thach town, Lap Thach district, Vinh Phuc province	49%	49%	General, Specialized, and Dental Clinic
Golab Ha Tinh Diagnostic Center Joint Stock Company	127, Hai Thuong Lan Ong Street, Bac Ha Ward, Ha Tinh City, Ha Tinh Province	35%	35%	General, Specialized, and Dental Clinic
Golab Tuyen Quang Diagnostic Center Joint Stock Company	1st Floor, No. 23, Hoa Lu Street, Group 01, Phan Thiet Ward, Tuyen Quang City, Tuyen Quang Province	35%	35%	General, Specialized, and Dental Clinic
Golab Cao Bang Test Center Joint Stock Company	Floor 1, No. 78 Dong Khe Street, Group 7, Tan Giang Ward, Cao Bang Province, Vietnam	20%	20%	General, Specialized, and Dental Clinic
Famicare Bac Ninh Joint Stock Company	Dinh Quarter, Pho Moi Ward, Que Vo Town, Bac Ninh Province, 2nd Floor, No. 65 Tran Tat Van Street, Phu Lien Ward, Kien An District, Hai Phong City	45%	45%	General, Specialized, and Dental Clinic
Famicare Hai Phong Joint Stock Company	1st Floor No. 140 Tue Tinh Street, Nam Thanh Ward, Ninh Binh City, Ninh Binh Province	45%	45%	General, Specialized, and Dental Clinic
Famicare Ninh Binh Joint Stock Company	Lot 58, Ton That Tung, Phu Dong Ward, Pleiku City-Gia Lai	48%	48%	General, Specialized, and Dental Clinic
Golab Gia Lai Diagnostic Center Joint Stock Company	179 Giai Phong Street, Dong Tam Ward, Hai Ba Trung District, Hanoi City	49%	49%	General, Specialized, and Dental Clinic
Famicare Huu Nghi Joint Stock Company	1st Floor, Lot 58 Ton That Tung, Phu Dong Ward, Pleiku City, Gia Lai Province, Vietnam	49%	49%	General, Specialized, and Dental Clinic
Famicare Gia Lai Joint Stock Company	2nd Floor, No. 83 Cu Chinh Lan Street, Group 13, Dong Tien Ward, Hoa Binh City, Hoa Binh Province, Vietnam	48%	48%	General, Specialized, and Dental Clinic
Famicare Hoa Binh Joint Stock Company	No. 127, Hai Thuong Lan Ong Street, Bac Ha Ward, Ha Tinh City, Ha Tinh Province, Vietnam	45%	45%	General, Specialized, and Dental Clinic
Famicare Ha Tinh Joint Stock Company	No. 22 Ho Tong Thoc Street, Hamlet 15, Nghi Phu Commune, Vinh City, Nghe An Province, Vietnam	45%	45%	General, Specialized, and Dental Clinic
Famicare Nghe An Joint Stock Company	115 Nguyen Trai, Group 4, Quang Phu Ward, Quang Ngai City, Quang Ngai Province, Vietnam	48%	48%	General, Specialized, and Dental Clinic
Famicare Quang Ngai Joint Stock Company	1st Floor, No. 114 Hai Phong Street,	45%	45%	General, Specialized,



**AMERICAN VIETNAMESE BIOTECH INCORPORATION**

Address: 4th Floor, Phu Ma Duong Building, No. 85 Hoang Van Thai Street, Tan My Ward, Ho Chi Minh City, Vietnam

For the six-month period of the financial year ending 31 December 2025

**Notes to the Interim Consolidated Financial Statements (continued)**

<b>Company name</b>	<b>Head office address</b>	<b>Ownership ratio</b>	<b>Voting ratio</b>	<b>Main business lines</b>
Center Joint Stock Company	Thach Thang Ward, Hai Chau District, Da Nang City, Vietnam			and Dental Clinic
Golab Vinh Yen Diagnostic Center Joint Stock Company	1st Floor, No. 79 Ba Trieu Street, Lien Bao Ward, Vinh Yen City, Vinh Phuc Province, Vietnam	49%	49%	General, Specialized, and Dental Clinic
Golab Bac Giang Test Center Joint Stock Company	Floor 1, No. 585 Le Loi Street, Bac Giang Ward, Bac Ninh Province, Vietnam	25%	25%	General, Specialized, and Dental Clinic
Famicare Tay Ninh Joint Stock Company	572A, 30/4 Street, Quarter 5, Ward 3, Tay Ninh City, Tay Ninh Province	49%	49%	General, Specialized, and Dental Clinic
Golab Hai Duong Diagnostic Center Joint Stock Company	1st Floor, No. 274, Nguyen Luong Bang, Viet Hoa Ward, Hai Duong City, Hai Duong Province	35%	35%	General, Specialized, and Dental Clinic
Golab Quang Tri Diagnostic Center Joint Stock Company	Ground Floor, No. 287, Hung Vuong Street, Dong Luong Ward, Dong Ha City, Quang Tri Province	49%	49%	General, Specialized, and Dental Clinic
Famicare Kontum Joint Stock Company	1st Floor, No. 370, Ba Trieu Street, Quang Trung Ward, Kon Tum City, Kon Tum Province	49%	49%	General, Specialized, and Dental Clinic
Golab Dien Bien Test Center Joint Stock Company	Floor 1, No. 01, Residential Group 10, Muong Thanh Ward, Dien Bien Province, Vietnam	48%	48%	General, Specialized, and Dental Clinic
Golab Dak Nong Test Center Joint Stock Company	Ground Floor, No. 169 Hung Vuong Street, Dong Gia Nghia Ward, Lam Dong Province, Vietnam	30%	30%	General, Specialized, and Dental Clinic
Golab Bac Ninh Diagnostic Center Joint Stock Company	Dinh Street, Pho Moi Ward, Que Vo Town, Bac Ninh Province	35%	35%	General, Specialized, and Dental Clinic
Golab Hai Phong Diagnostic Center Joint Stock Company	No. 65, Tran Tat Van Street, Phu Lien Ward, Kien An District, Hai Phong City	35%	35%	General, Specialized, and Dental Clinic
Famicare Binh Dinh Joint Stock Company	1st Floor, No. 191 Nguyen Hue, Tran Phu Ward, Quy Nhon City, Binh Dinh Province	48%	48%	General, Specialized, and Dental Clinic
Famicare 3/2 Joint Stock Company	484 3/2 Street, Ward 14, District 10, Ho Chi Minh City, Vietnam	48%	48%	General, Specialized, and Dental Clinic
Famicare Soc Trang Joint Stock Company	2nd Floor, No. 438 Le Duan Street, Hamlet 4, Ward 4, Soc Trang City, Soc Trang Province	48%	48%	General, Specialized, and Dental Clinic
Golab Binh Dinh Diagnostic Center Joint Stock Company	Ground Floor, No. 191 Nguyen Hue, Tran Phu Ward, Quy Nhon City, Binh Dinh Province	48%	48%	General, Specialized, and Dental Clinic
Golab Dak Lak Diagnostic Center Joint Stock Company	Basement, No. 161 Tran Quy Cap, Tu An Ward, Buon Ma Thuot City, Dak Lak Province	49%	49%	General, Specialized, and Dental Clinic
Golab Son La Test Center Joint Stock Company	Land lot No. 21a, 21b, Map sheet No. 3/S-, Group 17, Chieng Sinh Ward, Son La Province, Vietnam	30%	30%	General, Specialized, and Dental Clinic

**AMERICAN VIETNAMESE BIOTECH INCORPORATION**

Address: 4th Floor, Phu Ma Duong Building, No. 85 Hoang Van Thai Street, Tan My Ward, Ho Chi Minh City, Vietnam

For the six-month period of the financial year ending 31 December 2025

**Notes to the Interim Consolidated Financial Statements (continued)**

<b>Company name</b>	<b>Head office Totalress</b>	<b>Owne rship ratio</b>	<b>Votin g ratio</b>	<b>Main business lines</b>
Famicare Bien Hoa (Dong Nai) Joint Stock Company	No. 33 Dong Khoi Street, Ward 7, Binh Da Ward, Bien Hoa City, Dong Nai Province	35%	35%	General, Specialized, and Dental Clinic
Golab Tan An Diagnostic Center Joint Stock Company (Long An)	76 Nguyen Thong, Ward 3, Tan An City, Long An Province	35%	35%	General, Specialized, and Dental Clinic
Famicare Da Nang Joint Stock Company	2nd Floor, No. 114 Hai Phong Street, Thach Thang Ward, Hai Chau District, Da Nang City	45%	45%	General, Specialized, and Dental Clinic
Golab Thu Duc Diagnostic Center – Healthcare Q12 Joint Stock Company	Room 101, 28 Hien Vuong, Hiep Phu Ward, Thu Duc City, Ho Chi Minh City	22%	22%	General, Specialized, and Dental Clinic
Golab Ca Mau Test Center Joint Stock Company	Land lot No. 28, Map sheet No. 06, Street No. 13, Quarter 6, Hoa Thanh Ward, Ca Mau Province, Vietnam	49%	49%	General, Specialized, and Dental Clinic
Famicare Hai Duong Joint Stock Company	2nd Floor, No. 274 Nguyen Luong Bang, Thanh Binh Ward, Hai Duong City, Hai Duong Province, Vietnam	35%	35%	General, Specialized, and Dental Clinic
Golab Quang Binh Diagnostic Center Joint Stock Company	Cluster 1, Residential Group 14, Nam Ly Ward, Dong Hoi City, Quang Binh Province, Vietnam	35%	35%	General, Specialized, and Dental Clinic
Golab Vinh Phuc Diagnostic Center Joint Stock Company	1st Floor, House No. 52, Go Xoan Area, Nhan My Village, Thanh Van Commune, Tam Duong District, Vinh Phuc Province, Vietnam	35%	35%	General, Specialized, and Dental Clinic
Famicare Nam Dinh Joint Stock Company	Floor 2, No. 347 Phu Nghia Street, Thien Truong Ward, Ninh Binh Province, Vietnam	49%	49%	General, Specialized, and Dental Clinic
Famicare Vinh Long Joint Stock Company	1st Floor, No. 64/12C, Tran Phu Street, Hamlet 5, Ward 4, Vinh Long City, Vinh Long Province	35%	35%	General, Specialized, and Dental Clinic
Golab Kien Giang Diagnostic Center Joint Stock Company	Ground Floor, C31-P8, 3/2 Street, An Hoa Ward, Rach Gia City, Kien Giang Province, Vietnam	35%	35%	General, Specialized, and Dental Clinic
Famicare Bac Lieu Joint Stock Company	1st Floor, No. 210, Ba Trieu Street, Ward 3, Bac Lieu City, Bac Lieu Province	35%	35%	General, Specialized, and Dental Clinic
Famicare Go Vap Joint Stock Company	Ground Floor, No. 178 Nguyen Thai Son, Ward 4, Go Vap District, Ho Chi Minh City	48%	48%	General, Specialized, and Dental Clinic
Famicare Long An Joint Stock Company	76 Nguyen Thong, Ward 3, Tan An City, Long An Province	49%	49%	General, Specialized, and Dental Clinic
Famicare District 5 Joint Stock Company	26 Tan Thanh, Ward 12, District 5, Ho Chi Minh City	49%	49%	General, Specialized, and Dental Clinic
Famicare Ca Mau Joint Stock Company	Land lot No. 28, Map sheet No. 06, Street No. 13, Quarter 6, Hoa Thanh Ward, Ca Mau Province, Vietnam	26%	26%	General, Specialized, and Dental Clinic
Famicare Son La Joint Stock Company	and lot No. 86, Map sheet No. 106-96, Group 17, Sang Hamlet, Chieng Sinh	49%	49%	General, Specialized, and Dental Clinic



**AMERICAN VIETNAMESE BIOTECH INCORPORATION**

Address: 4th Floor, Phu Ma Duong Building, No. 85 Hoang Van Thai Street, Tan My Ward, Ho Chi Minh City, Vietnam

For the six-month period of the financial year ending 31 December 2025

**Notes to the Interim Consolidated Financial Statements (continued)**

<b>Company name</b>	<b>Head office Totalress</b>	<b>Owne rship ratio</b>	<b>Votin g ratio</b>	<b>Main business lines</b>
	Ward, Son La Province, Vietnam			
Golab Tra Vinh Diagnostic Center Joint Stock Company	Nguyen Dang Street, Hamlet 7, Ward 7, Tra Vinh City, Tra Vinh Province	35%	35%	General, Specialized, and Dental Clinic
Golab An Giang Diagnostic Center Joint Stock Company	177 Ung Van Khiem Street, My Phuoc Ward, Long Xuyen City, An Giang Province	35%	35%	General, Specialized, and Dental Clinic
Famicare Kien Giang Joint Stock Company	1st Floor, C31-P8, 3/2 Street, An Hoa Ward, Rach Gia City, Kien Giang Province	35%	35%	General, Specialized, and Dental Clinic
Famicare An Giang Joint Stock Company	Ground floor, 177 Ung Van Khiem Street, My Phuoc Ward, Long Xuyen City, An Giang Province	49%	49%	General, Specialized, and Dental Clinic
Famicare Thu Dau Mot Joint Stock Company	634, Binh Duong Boulevard, Zone 5, Hiep Thanh Ward, Thu Dau Mot City, Binh Duong Province	49%	49%	General, Specialized, and Dental Clinic
Famicare Dong Thap Joint Stock Company	Ground floor, No. 102 Nguyen Van Tre extended street, Dong Thap Hospital Residential Area, My Tan Commune, Cao Lanh City, Dong Thap Province	49%	49%	General, Specialized, and Dental Clinic
Famicare Tien Giang Joint Stock Company	Ground Floor, No. 368A, Phuoc Hoa Hamlet, Phuoc Thanh Commune, My Tho City, Tien Giang Province, Vietnam	49%	49%	General, Specialized, and Dental Clinic
Famicare Tra Vinh Joint Stock Company	Land plot number 795, Map sheet number 9, Nguyen Dang Street, Hamlet 7, Ward 7, Tra Vinh City, Tra Vinh Province	49%	49%	General, Specialized, and Dental Clinic
Golab Bien Hoa Diagnostic Center Joint Stock Company	No. 33, Dong Khoi Street, Group 23, Quarter 3, Tam Hoa Ward, Bien Hoa City, Dong Nai Province	35%	35%	General, Specialized, and Dental Clinic
Golab Vinh Long Diagnostic Center Joint Stock Company	Ground Floor, No. 64/12C, Tran Phu Street, Hamlet 5, Ward 4, Vinh Long City, Vinh Long Province, Vietnam	35%	35%	General, Specialized, and Dental Clinic
Amicare Quang Nam Joint Stock Company	Floor 1, No. 196 Trung Nu Vuong Street, Ban Thach Ward, Da Nang City, Vietnam	48%	48%	General, Specialized, and Dental Clinic

**d. Dependent accounting units:**

<b>Name</b>	<b>Address</b>	<b>Main Activities</b>
Representative Office of Viet My Pharmaceutical and Medical Equipment Production and Trading Joint Stock Company	A30-A31, D1 Street, Tan Hai Minh Residential Area, KP1, Thu Duc Ward, Ho Chi Minh City	Trading of pharmaceuticals; purchase and sale of medical equipment, instruments, and laboratory chemicals (Normal operations)
Branch of Viet My Pharmaceutical and Medical Equipment Production and Trading Joint Stock Company	2nd Floor, Lot No. 36, BT5 Phap Van – Tu Hiep New Urban Area, Yen So Ward, Hanoi City, Vietnam	Trading of pharmaceuticals; purchase and sale of medical equipment, instruments, and laboratory chemicals (Normal operations)

## **AMERICAN VIETNAMESE BIOTECH INCORPORATION**

Address: 4th Floor, Phu Ma Duong Building, No. 85 Hoang Van Thai Street, Tan My Ward, Ho Chi Minh City, Vietnam

For the six-month period of the financial year ending 31 December 2025

### **Notes to the Interim Consolidated Financial Statements (continued)**

---

#### **II. FISCAL YEAR, CURRENCY USED IN ACCOUNTING**

##### **1. Fiscal year**

The Company's fiscal year begins on January 1 and ends on December 31 of each year.

##### **2. Currency used in accounting**

The currency used in accounting is Vietnamese Dong (VND) because revenue and expenditure are mainly made in VND.

#### **III. ACCOUNTING STANDARDS AND REGIMES APPLIED**

##### **1. Applicable accounting standards**

The Company applies the Vietnamese Accounting Standards and the Corporate Accounting Regime issued under Circular No. 200/2014/TT-BTC dated December 22, 2014, Circular No. 53/2016/TT-BTC in 2016 amending and supplementing Circular No. 200/2014/TT-BTC, Circular No. 202/2014/TT-BTC dated December 22, 2014, as well as other circulars issued by the Ministry of Finance providing guidance on the implementation of accounting standards in the preparation of the financial statements.

##### **2. Statement on compliance with accounting standards and accounting regimes**

The Company's Management ensures compliance with the requirements of the Vietnamese Accounting Standards and the Corporate Accounting Regime issued under Circular No. 200/2014/TT-BTC dated December 22, 2014, Circular No. 53/2016/TT-BTC in 2016 amending and supplementing Circular No. 200/2014/TT-BTC, Circular No. 202/2014/TT-BTC dated December 22, 2014, as well as other circulars issued by the Ministry of Finance providing guidance on the implementation of accounting standards in the preparation of the financial statements.

#### **IV. ACCOUNTING POLICIES APPLIED**

##### **1. Basis for preparing Consolidated Financial Statements**

Financial statements are prepared on the accrual basis of accounting (except for information relating to cash flows).

The consolidated financial statements include the Financial Statements of American Vietnamese Biotech INC.(parent company) and subsidiaries. A subsidiary is an entity that is controlled by the parent company. Control exists when the parent company has the power, directly or indirectly, to govern the financial and operating policies of a subsidiary so as to obtain benefits from its activities. In assessing control, potential voting rights that are currently exercisable or convertible are taken into account.

The results of operations of subsidiaries acquired or sold during the year are presented in the Consolidated Statement of Income from the date of acquisition or up to the date of sale of the investment in that subsidiary.

In case the accounting policy of a subsidiary is different from the accounting policy applied consistently in the Group, the Financial Statements of the subsidiary will be appropriately adjusted before being used for preparing the Consolidated Financial Statements.

Balances of accounts on the Balance Sheet between companies in the same Group, intra-group transactions, unrealized intra-group profits arising from these transactions are eliminated when



## **AMERICAN VIETNAMESE BIOTECH INCORPORATION**

Address: 4th Floor, Phu Ma Duong Building, No. 85 Hoang Van Thai Street, Tan My Ward, Ho Chi Minh City, Vietnam

For the six-month period of the financial year ending 31 December 2025

### **Notes to the Interim Consolidated Financial Statements (continued)**

preparing the Consolidated Financial Statements. Unrealized losses arising from intra-group transactions are also eliminated unless the costs creating such losses are unrecoverable.

Non-controlling interests represent the portion of the profits and net assets of a subsidiary not held by the parent company's shareholders and are presented separately in the consolidated income statement and consolidated balance sheet. Minority interests consist of the amount of the minority interests at the date of the original business combination and the minority's share of changes in equity since the date of the combination. LossesThe minority interest in excess of its interest in the subsidiary's equity is deducted from the Group's interest unless the minority has a binding obligation and is able to make good the loss.

#### **2. Business combination**

The assets, liabilities and contingent liabilities of the company are measured at their fair values at the date of acquisition. Any Totalitional difference between the purchase price and the fair value of the assets acquired is recognised as goodwill. Any negative difference between the purchase price and the fair value of the assets acquired is recognised in the income statement for the period in which the subsidiary is acquired.

Non-controlling interests at the date of the initial business combination are measured based on the non-controlling interest's share of the fair value of the assets, liabilities and contingent liabilities recognised.

#### **3. Cash and cash equivalents**

Cash includes cash on hand, demand deposits, monetary gold used for value storage purposes, excluding gold classified as inventories used as raw materials for the production of products or goods for sale.

Cash equivalents are short-term investments with a maturity of no more than three months from the date of purchase, which are readily convertible to known amounts of cash and are subject to an insignificant risk of changes in value.

#### **4. Financial investments**

##### ***Loans***

Loans are measured at cost less allowance for doubtful debts. Allowance for doubtful debts on loans is made based on the expected level of loss that may occur.

##### ***Investments in joint ventures and associates***

Investments in associates are initially recognized at cost, including the purchase price or capital contribution plus costs directly attributable to the investment. In the case of investments in non-monetary assets, the cost of the investment is recognized at the fair value of the non-monetary assets at the time of acquisition.

Dividends and profits from periods prior to the investment being purchased are recorded as a reduction in the value of the investment itself. Dividends and profits from periods subsequent to the investment being purchased are recorded as revenue. Dividends received in shares are only tracked by the number of shares increased, not the value of the shares received/recorded at par value.

Provision for losses on investments in associates is made when the associate suffers a loss, with the provision equal to the difference between the actual capital contributions of the parties in the joint

## **AMERICAN VIETNAMESE BIOTECH INCORPORATION**

Address: 4th Floor, Phu Ma Duong Building, No. 85 Hoang Van Thai Street, Tan My Ward, Ho Chi Minh City, Vietnam

For the six-month period of the financial year ending 31 December 2025

### **Notes to the Interim Consolidated Financial Statements (continued)**

venture or associate and the actual equity multiplied by the ratio of the Enterprise's capital contribution to the total actual capital contributions of the parties in the associate. If the associate is the subject of the Consolidated Financial Statements, the basis for determining the provision for losses is the Consolidated Financial Statements.

Increases and decreases in the provision for investment losses in associates that need to be set up at the end of the fiscal year are recorded in financial expenses.

#### ***Investments in equity instruments of other entities***

Investments in equity instruments of other entities include investments in equity instruments but the Enterprise does not have control, joint control or significant influence over the investee.

Investments in equity instruments of other entities are initially recorded at cost, including the purchase price or capital contribution plus direct costs related to the investment. Dividends and profits from periods prior to the investment being purchased are recorded as a reduction in the value of the investment itself. Dividends and profits from periods subsequent to the investment being purchased are recorded as revenue. Dividends received in shares are only tracked by the number of Totalitional shares, not recording the value of shares received/recorded at par value (except for state-owned enterprises in accordance with current regulations of law).

Provision for losses on investments in equity instruments of other entities is made as follows:

- For investments in listed shares or for which the fair value of the investment is reliably determined, the provision is based on the market value of the shares.
- For investments whose fair value cannot be determined at the reporting date, provisions are made based on the loss of the investee with the provision equal to the difference between the actual capital contribution of the parties at other entities and the actual equity multiplied by the capital contribution ratio of the Enterprise compared to the total actual capital contribution of the parties at other entities.

Increases and decreases in the provision for investment losses in equity instruments of other entities that need to be set up at the end of the fiscal year are recorded in financial expenses.

## **5. Accounts Receivable**

Accounts receivable are stated at carrying amount less allowance for doubtful debts.

The classification of receivables as trade receivables and other receivables is carried out according to the following principles:

- Trade receivables reflect commercial receivables arising from purchase-sale transactions between the company and buyers who are independent entities, including receivables from export sales entrusted to other entities.
- Other receivables reflect non-commercial receivables not related to purchase and sale transactions.

Provision for doubtful debts is made for each doubtful debt based on the age of overdue debts or the expected level of loss that may occur, specifically as follows:

- For overdue receivables:
  - 30% of the value for overdue receivables from 6 months to less than 1 year.
  - 50% of the value for overdue receivables from 1 year to less than 2 years.



**AMERICAN VIETNAMESE BIOTECH INCORPORATION**

Address: 4th Floor, Phu Ma Duong Building, No. 85 Hoang Van Thai Street, Tan My Ward, Ho Chi Minh City, Vietnam

For the six-month period of the financial year ending 31 December 2025

**Notes to the Interim Consolidated Financial Statements (continued)**

- 70% of the value for receivables overdue from 2 years to less than 3 years.
- 100% of the value for receivables 3 years or more old.
- For receivables that are not overdue but are unlikely to be recovered: establish provisions based on expected loss level.

**6. Inventory**

Inventories are goods and are stated at the lower of cost and net realizable value. The cost of inventories is determined including the cost of purchase and other directly relevant costs incurred in bringing the inventories to their present location and condition.

Net realizable value is the estimated selling price of inventories in the ordinary course of business, less the estimated costs of completion and the estimated costs necessary to make the sale. Inventories are valued at cost using the weighted average method and accounted for using the perpetual inventory method.

Provision for inventory devaluation is established for each inventory item whose original cost is greater than its net realizable value. For unfinished services, provision for devaluation is calculated for each type of service with a separate price. Increases and decreases in the balance of provision for devaluation of inventory required to be established at the end of the fiscal year are recorded in cost of goods sold.

**7. Prepaid expenses**

Prepaid expenses include actual expenses that have been incurred but are related to the results of production and business activities of many accounting periods. The company's prepaid expenses are the cost of tools and equipment.

***Tools, instruments***

Tools and equipment put into use are allocated to expenses using the straight-line method with an allocation period of no more than 03 years.

**8. Tangible fixed assets**

Tangible fixed assets are stated at cost less accumulated depreciation. The cost of tangible fixed assets includes all costs incurred by the company to acquire the fixed assets up to the time the assets are ready for use. Expenses incurred after initial recognition are only recorded as an increase in the cost of fixed assets if it is certain that these costs will increase future economic benefits from the use of the assets. Expenses incurred that do not satisfy the above conditions are recorded as production and business expenses in the period.

When tangible fixed assets are sold or disposed of, their cost and accumulated depreciation are eliminated from the accounts and any gain or loss resulting from their disposal is recognized as income or expense in the year.

Tangible fixed assets are depreciated using the straight-line method over their estimated useful lives. The depreciation years for various types of Tangible Fixed Assets are as follows:

<b><u>Type of fixed asset</u></b>	<b><u>Duration</u></b>
Buildings and structures	16
Machinery and equipment	06-10
Means of transport, transmission	05-10

## **AMERICAN VIETNAMESE BIOTECH INCORPORATION**

Address: 4th Floor, Phu Ma Duong Building, No. 85 Hoang Van Thai Street, Tan My Ward, Ho Chi Minh City, Vietnam

For the six-month period of the financial year ending 31 December 2025

### **Notes to the Interim Consolidated Financial Statements (continued)**

---

#### **9. Intangible fixed assets**

Intangible fixed assets are stated at cost less accumulated depreciation.

The original cost of intangible fixed assets includes all costs that Company must be spent to acquire fixed assets up to the time the asset is ready for use. Expenditures relating to intangible fixed assets incurred after initial recognition are recognised as expenses in the period in which they are incurred, unless they are associated with a specific intangible fixed asset and result in an increase in the economic benefits derived from the asset.

##### ***Software program***

Costs relating to computer software programs that are not an integral part of the related hardware are capitalized. The cost of computer software is the total cost incurred by the Company up to the date the software is put into use. Computer software is amortized on a straight-line basis over 10-20 years.

#### **10. Cost of unfinished construction**

Construction in progress reflects directly related costs (including including interest expenses related to the Company's accounting policies) to assets under construction, machinery and equipment being installed for production, leasing and management purposes as well as costs related to repairs of fixed assets in progress. These assets are recorded at original cost and not depreciated

#### **11. Accounts Payable and Accrued Expenses**

Liabilities and accruals are recognized for amounts to be paid in the future for goods and services received. Accruals are recognized based on reasonable estimates of the amounts to be paid.

The classification of payables as trade payables, accrued expenses, internal payables and other payables is carried out according to the following principles:

- Trade payables reflect commercial payables arising from transactions of purchasing goods, services, assets and the seller is an independent entity of the company, including payables when importing through consignees.
- Payable expenses reflect amounts payable for goods and services received from sellers or provided to buyers but not yet paid due to lack of invoices or insufficient accounting records and documents, and amounts payable to employees for leave wages, production and business expenses that must be accrued in advance.
- Other payables reflect non-commercial payables not related to the purchase, sale or provision of goods and services.

#### **12. Equity**

##### ***Owner's equity***

Owner's equity is recorded according to the actual capital contributed by shareholders.

##### ***Capital surplus***

Share capital surplus is recorded as the difference between the issue price and the par value of shares when first issued, Totalitional issued or the difference between the reissue price and the book value of treasury shares. Direct costs related to the Totalitional issuance of shares and reissuance of treasury shares are recorded as a decrease in share capital surplus.

##### ***Other owners' equity***

Other capital is formed by supplementing from business results, revaluation of assets and the remaining value between the fair value of donated, presented, and sponsored assets after deducting taxes payable (if any) related to these assets.



**AMERICAN VIETNAMESE BIOTECH INCORPORATION**

Address: 4th Floor, Phu Mã Duong Building, No. 85 Hoang Van Thai Street, Tan My Ward, Ho Chi Minh City, Vietnam

For the six-month period of the financial year ending 31 December 2025

**Notes to the Interim Consolidated Financial Statements (continued)**

---

**13. Profit Distribution**

Profit after corporate income tax is distributed to shareholders after setting aside funds according to the Company's Charter as well as legal regulations and approved by the General Meeting of Shareholders.

The distribution of profits to shareholders takes into account non-cash items in undistributed earnings that may affect cash flows and the ability to pay dividends. Gains from revaluation of assets contributed as capital, gains from revaluation of monetary items, financial instruments and other non-monetary items.

***Other funds***

Funds are set aside and used in accordance with the Company Charter and the Resolution of the Annual Shareholders' Meeting.

Dividends are recognized as liabilities when approved by the General Meeting of Shareholders.

**14. Revenue and income recognition*****a) Sales revenue***

Revenue from sales of goods is recognized when all of the following conditions are simultaneously satisfied:

- The company has transferred to the buyer the significant risks and rewards of ownership of the products or goods.
- The Company no longer holds title to the goods or control over the goods.
- Revenue is determined with relative certainty. When the contract stipulates that the buyer has the right to return the purchased products or goods under specific conditions, revenue is only recognized when those specific conditions no longer exist and the buyer is not entitled to return the products or goods (except in cases where the customer has the right to return the goods in exchange for other goods or services).
- The Company has obtained or will obtain economic benefits associated with the sale transaction.
- Identify the costs associated with a sales transaction

***b) Service revenue***

Revenue from a service transaction is recognised when the outcome of the transaction can be measured reliably. In cases where the service is performed over several periods, revenue is recognised in each period based on the results of the work completed at the end of the accounting period. The outcome of a service transaction is recognised when all of the following conditions are met:

- Revenue is measured reliably. When a contract provides that the buyer has the right to return the services purchased under specific conditions, revenue is recognized only when the specific conditions no longer exist and the buyer has no right to return the services provided.
- It is possible to obtain economic benefits from the transaction of providing that service.
- Determine the portion of work completed as of the end of the fiscal year.
- Identify the costs incurred for the transaction and the costs to complete the transaction to provide that service.

## AMERICAN VIETNAMESE BIOTECH INCORPORATION

Address: 4th Floor, Phu Ma Duong Building, No. 85 Hoang Van Thai Street, Tan My Ward, Ho Chi Minh City, Vietnam

For the six-month period of the financial year ending 31 December 2025

### Notes to the Interim Consolidated Financial Statements (continued)

---

#### *c) Interest*

Interest is recognized on an accrual basis, determined on the deposit account balance and the actual interest rate for each period.

#### *d) Dividends and profits distributed*

Dividends and profits distributed are recognized when the company is entitled to receive dividends or profits from capital contributions. Dividends received in shares are only tracked by the number of shares increased, not recorded at par value of shares received.

#### **15. Cost of goods sold.**

Cost of goods sold during the year is recorded in accordance with revenue generated during the period and ensures compliance with the principle of prudence.

#### **16. Borrowing costs**

Borrowing costs include interest and other costs incurred in connection with borrowing.

#### **17. Corporate income tax**

##### *Current income tax*

Current income tax is the tax that is calculated on taxable income. Taxable income differs from accounting profit due to adjustments for temporary differences between tax and accounting, non-deductible expenses as well as adjustments for non-taxable income and losses carried forward.

Subsidiaries: Hau Giang Medicare Clinic Joint Stock Company; Soc Trang Medicare Clinic Joint Stock Company; Nga Bay Medicare Clinic Joint Stock Company; Song Hau New Technology Application Research Joint Stock Company operating in areas with difficult and extremely difficult socio-economic conditions. According to the provisions of Point a, Clause 1, Article 15 and Point a, Clause 1, Article 16 of Decree No. 218/2013/ND-CP dated December 26, 2013 of the Government stipulating and guiding the implementation of the Law on Corporate Income Tax, amended and supplemented by Clause 16, Article 1 of Decree No. 12/2015/ND-CP dated February 12, 2015 of the Government. According to the above regulations, corporate income tax will be exempted for 4 years (from 2021 to 2024), 50% reduction in corporate income tax for the next 9 years from 2025 and a tax rate of 10% will be applied for 15 years from 2021.

Other activities The Company pays corporate income tax at a rate of 20%.

#### **18. Financial instruments**

##### **i. Financial assets**

##### *Classification of financial assets*

The Company classifies its financial assets into the following groups: financial assets at fair value through the Statement of Business Performance, investments held to maturity, loans and receivables, and available-for-sale financial assets. The classification of these financial assets depends on the nature and purpose of the financial assets and is determined at the time of initial recognition.

##### *Financial assets are recorded at fair value through the Statement of Business Performance*

Financial assets are classified as measured at fair value through the Statement of Income if they are held for trading or designated as such at fair value through the Statement of Income upon initial recognition.

Financial assets are classified as held for trading securities if:

- Purchased or created primarily for the purpose of resale in the short term;
- The Company intends to hold for the purpose of short-term profit;



## AMERICAN VIETNAMESE BIOTECH INCORPORATION

Address: 4th Floor, Phu Ma Duong Building, No. 85 Hoang Van Thai Street, Tan My Ward, Ho Chi Minh City, Vietnam

For the six-month period of the financial year ending 31 December 2025

### Notes to the Interim Consolidated Financial Statements (continued)

- Derivative financial instruments (except for derivative financial instruments that are identified as a financial guarantee contract or a designated and effective hedging instrument).

#### *Held to maturity investments*

Held-to-maturity investments are non-derivative financial assets with fixed or determinable payments and fixed maturity that the Company has the intention and ability to hold to maturity.

#### *Loans and receivables*

Loans and receivables are non-derivative financial assets with fixed or determinable payments and are not listed on an active market.

#### *Financial assets available for sale*

Available-for-sale financial assets are non-derivative financial assets that are designated as available-for-sale or that are not classified as financial assets at fair value through profit or loss, held-to-maturity investments, or loans and receivables.

#### *Initial book value of financial assets*

Financial assets are recognised at the date of acquisition and derecognised at the date of sale. At the time of initial recognition, financial assets are measured at their purchase price/issuance costs plus any other costs directly attributable to the acquisition or issue of the financial asset.

## ii. Financial liabilities

The Company classifies financial liabilities into groups: financial liabilities recorded at fair value through the Income Statement, financial liabilities determined at amortized cost. The classification of financial liabilities depends on the nature and purpose of the financial liability and is determined at the time of initial recognition.

#### *Financial liabilities are recorded at fair value through the Statement of Income.*

A financial liability is classified as measured at fair value through the Statement of Income if it is held for trading or designated as such at fair value through the Statement of Income upon initial recognition.

Financial liabilities are classified as held for trading securities if:

- Issued or created primarily for the purpose of repurchasing in the short term;
- The Company intends to hold for the purpose of short-term profit;
- Derivative financial instruments (except for derivative financial instruments that are identified as a financial guarantee contract or a designated and effective hedging instrument).

#### *Financial liabilities are measured at amortized cost.*

Financial liabilities are measured at amortised cost, which is the amount at which the financial liability is initially recognised minus principal repayments, plus or minus the cumulative amortisation using the effective interest method of any difference between that initial amount and the maturity amount, and minus any reduction (directly or through the use of an allowance account) for impairment or uncollectibility.

The effective interest method is a method of calculating the amortized cost of a financial liability or group of financial liabilities and allocating interest income or expense over the relevant period. The effective interest rate is the rate at which estimated future cash flows that will be paid or received over the expected life of the financial instrument or, if appropriate, shorter, are discounted to the net present carrying amount of the financial liability.

#### *Initial book value of financial liability*

At initial recognition, financial liabilities are measured at issue price plus any costs directly attributable to the issue of the financial liability.

**AMERICAN VIETNAMESE BIOTECH INCORPORATION**

Address: 4th Floor, Phu Ma Duong Building, No. 85 Hoang Van Thai Street, Tan My Ward, Ho Chi Minh City, Vietnam

For the six-month period of the financial year ending 31 December 2025

**Notes to the Interim Consolidated Financial Statements (continued)****iii. Equity instruments**

An equity instrument is a contract that evidences a residual interest in the assets of the Company after deducting all of its liabilities.

**19. Related parties**

Parties are considered to be related if one party has the ability to control the other party or exercise significant influence over the other party in making financial and operating decisions. Parties are also considered to be related if they are subject to common control or common significant influence.

In considering any related party relationship, attention is directed more to the substance of the relationship than to the legal form.

In considering any related party relationship, attention is directed more to the substance of the relationship than to the legal form.

Transactions with related parties during the period are presented in note VIII.1.

**V. SUPPLEMENTARY INFORMATION ON ITEMS PRESENTED IN THE INTERIM CONSOLIDATED BALANCE SHEET****1. Cash and cash equivalents**

	<b>Ending balance</b>	<b>Beginning balance</b>
Cash on hand	10,566,614,973	1,885,137,331
Bank demand deposits	2,586,145,403	14,309,043,426
<b>Total</b>	<b>13,152,760,376</b>	<b>16,194,180,757</b>

**2. Held-to-maturity investments**

	<b>Ending balance</b>		<b>Beginning balance</b>	
	<b>Cost</b>	<b>Fair value</b>	<b>Cost</b>	<b>Fair value</b>
<i>Short-term</i>	<i>98,300,000</i>	<i>98,300,000</i>	<i>98,300,000</i>	<i>98,300,000</i>
Term Deposits	98,300,000	98,300,000	98,300,000	98,300,000
<b>Total</b>	<b>98,300,000</b>	<b>98,300,000</b>	<b>98,300,000</b>	<b>98,300,000</b>

**3. Short-term trade receivables**

	<b>Ending balance</b>		<b>Beginning balance</b>	
	<b>Value</b>	<b>Provision</b>	<b>Value</b>	<b>Provision</b>
<i>Receivables from Related Parties</i>	<i>57,795,580,000</i>	<i>-</i>	<i>174,642,328,400</i>	<i>-</i>
Medicare Huu Nghi General Clinic Joint Stock Company	-	-	2,644,530,000	-
Golab Phap Van Laboratory Center Joint Stock Company	38,500,000	-	7,362,660,000	-
Golab Nam Dinh Test Center Joint Stock Company	273,000,000	-	-	-
Golab Hai Duong Laboratory Center Joint Stock Company	940,000,000	-	9,784,494,700	-
Golab Thai Binh Test Center Joint Stock Company	100,000,000	-	-	-
Golab Thanh Hoa Test Center Joint Stock Company	273,000,000	-	-	-
Golab Hue Test Center Joint Stock Company	2,362,500,000	-	-	-



**AMERICAN VIETNAMESE BIOTECH INCORPORATION**

Address: 4th Floor, Phu Ma Duong Building, No. 85 Hoang Van Thai Street, Tan My Ward, Ho Chi Minh City, Vietnam

For the six-month period of the financial year ending 31 December 2025

**Notes to the Interim Consolidated Financial Statements (continued)**

	Ending balance		Beginning balance	
	Value	Provision	Value	Provision
Golab Binh Thuan Test Center Joint Stock Company	2,073,750,000	-	-	-
Golab Binh Phuoc Test Center Joint Stock Company	2,226,000,000	-	-	-
Golab Quang Nam Test Center Joint Stock Company	5,873,660,000	-	-	-
Golab Khanh Hoa Test Center Joint Stock Company	2,073,750,000	-	-	-
Golab Ninh Thuan Test Center Joint Stock Company	273,000,000	-	-	-
Golab Cao Bang Test Center Joint Stock Company	2,514,750,000	-	-	-
Golab Ha Giang Test Center Joint Stock Company	273,000,000	-	-	-
Golab Son La Test Center Joint Stock Company	99,000,000	-	-	-
Golab Lam Dong Test Center Joint Stock Company	4,299,750,000	-	-	-
Golab Dak Nong Test Center Joint Stock Company	273,000,000	-	-	-
Ba Dinh Clinic Joint Stock Company	2,073,750,000	-	-	-
Golab Hai Phong Laboratory Center Joint Stock Company	-	-	2,932,070,200	-
Golab Hung Yen Laboratory Center Joint Stock Company	-	-	7,013,194,700	-
Golab Quang Binh Laboratory Center Joint Stock Company	-	-	7,543,540,200	-
Golab Dong Thap Laboratory Center Joint Stock Company	-	-	2,768,270,200	-
Golab Vinh Long Laboratory Center Joint Stock Company	-	-	2,768,270,200	-
Golab An Giang Laboratory Center Joint Stock Company	-	-	6,525,700,200	-
Famicare Kien Giang Joint Stock Company	-	-	4,335,384,500	-
Golab Kien Giang Laboratory Center Joint Stock Company	-	-	9,550,370,200	-
Golab Bac Ninh Laboratory Center Joint Stock Company	-	-	9,753,594,700	-
Golab Vinh Phuc Laboratory Center Joint Stock Company	-	-	9,165,214,500	-
Medicare Ninh Binh General Clinic Joint Stock Company	38,500,000	-	2,443,230,000	-
Golab Ha Tinh Laboratory Center Joint Stock Company	-	-	6,786,114,500	-
Famicare Quang Binh Joint Stock Company	-	-	4,315,384,500	-
Golab Bien Hoa Laboratory Center Joint Stock Company	5,639,160,000	-	9,643,160,000	-
Golab Gia Lai Laboratory Center Joint Stock Company	-	-	6,717,870,200	-
Famicare Vinh Long Joint Stock Company	-	-	7,075,694,700	-

**AMERICAN VIETNAMESE BIOTECH INCORPORATION**

Address: 4th Floor, Phu Ma Duong Building, No. 85 Hoang Van Thai Street, Tan My Ward, Ho Chi Minh City, Vietnam

For the six-month period of the financial year ending 31 December 2025

**Notes to the Interim Consolidated Financial Statements (continued)**

	Ending balance		Beginning balance	
	Value	Provision	Value	Provision
Company				
Golab Tan An Laboratory Center Joint Stock Company	-	-	2,822,420,200	-
Golab Tuyen Quang Laboratory Center Joint Stock Company	46,660,000	-	5,600,660,000	-
Golab Da Nang Laboratory Center Joint Stock Company	2,400,440,000	-	10,085,770,000	-
Golab Tay Ninh Laboratory Center Joint Stock Company	-	-	5,600,660,000	-
Golab Tra Vinh Laboratory Center Joint Stock Company	-	-	2,400,330,000	-
Nghe An General Clinic Joint Stock Company	875,830,000	-	6,200,660,000	-
Golab Tien Giang Laboratory Center Joint Stock Company	5,600,660,000	-	5,600,660,000	-
Golab Bac Lieu Laboratory Center Joint Stock Company	4,920,660,000	-	5,600,660,000	-
Golab Kon Tum Laboratory Center Joint Stock Company	1,800,330,000	-	1,800,330,000	-
Golab Go Vap Laboratory Center Joint Stock Company	3,715,660,000	-	5,600,660,000	-
Golab Quang Tri Laboratory Center Joint Stock Company	1,920,440,000	-	2,400,440,000	-
Golab Quang Ngai Laboratory Center Joint Stock Company	1,800,330,000	-	1,800,330,000	-
Golab Ben Tre Test Center Joint Stock Company	193,000,000	-	-	-
Golab Yen Bai Test Center Joint Stock Company	2,514,750,000	-	-	-
Golab Thai Nguyen Test Center Joint Stock Company	288,750,000	-	-	-
<b>Receivables from Other Customers</b>	<b>83,604,172,110</b>	<b>(628.258.204)</b>	<b>122,486,890,682</b>	<b>(1,801,022,208)</b>
Nhat Medical Equipment Co., Ltd,	17,405,000,000	-	11,632,794,800	-
Lou Investment Joint Stock Company	35,931,796,291	-	43,204,799,712	-
Sara Hospital Investment Joint Stock Company	-	-	5,414,825,753	-
Hoa Binh Agricultural Machinery Investment Joint Stock Company	13,377,000,000	-	-	-
Can Tho Laboratory and Environment Center Joint Stock Company	-	-	45,502,587,900	-
Other customers	16,890,375,819	(628.258.204)	16,731,882,517	(1,801,022,208)
<b>Total</b>	<b>141,399,752,110</b>	<b>(628.258.204)</b>	<b>297,129,219,082</b>	<b>(1,801,022,208)</b>



**AMERICAN VIETNAMESE BIOTECH INCORPORATION**

Address: 4th Floor, Phu Ma Duong Building, No. 85 Hoang Van Thai Street, Tan My Ward, Ho Chi Minh City, Vietnam

For the six-month period of the financial year ending 31 December 2025

**Notes to the Interim Consolidated Financial Statements (continued)****4. Short-term Advances to Suppliers**

	Ending balance		Beginning balance	
	Value	Provision	Value	Provision
<i>Current advances to suppliers</i>	<b>83,981,479,039</b>	<b>(7,221,250,000)</b>	<b>540,213,205,047</b>	<b>(20,593,000,000)</b>
Can Tho High-Tech Investment Joint Stock Company (*)	24,000,000,000	-	55,450,000,000	-
Can Tho Laboratory and Environment Center Joint Stock Company (*)	6,073,100,000	(2,885,250,000)	93,400,000,000	(12,000,000,000)
Nha Trang Medical Hi-Tech Application Joint Stock Company (*)	-	-	5,000,000,000	-
Hoa Binh Agricultural Machinery Investment Joint Stock Company (*)	17,279,750,000	-	131,346,000,000	-
Sara Hospital Investment Joint Stock Company (*)	-	-	33,566,000,000	-
Lou Investment Joint Stock Company (*)	-	-	40,000,000,000	-
Japan Kanpeki Joint Stock Company	7,399,579,656	-	7,277,996,973	-
High-Tech Medical Environment Company Limited (*)	18,600,000,000	(4,336,000,000)	97,311,340,000	(8,593,000,000)
Nhat Medical Equipment Company Limited (*)	8,999,000,000	-	75,379,000,000	-
Other suppliers	1,630,049,383	-	1,482,868,074	-
<b>Total</b>	<b>83,981,479,039</b>	<b>(7,221,250,000)</b>	<b>540,213,205,047</b>	<b>(20,593,000,000)</b>

(\*) These are advance payments made for the purchase of machinery, software, and medical equipment to serve the Company's business operations. However, the delivery period has passed and the suppliers have not yet carried out the procedures for handover. As of the reporting date, the outstanding advances that have not been recovered amounted to VND 77,700,850,000.

**5. Short-term Loans Receivable**

	Ending balance	Beginning balance
<i>Receivables from Related Parties (*)</i>	<b>7,815,000,000</b>	<b>15,250,000,000</b>
Golab Binh Duong Testing Center Joint Stock Company	-	500,000,000
Golab Tan An Testing Center Joint Stock Company	-	1,750,000,000
Famicare Long An Joint Stock Company	1,500,000,000	1,500,000,000
Famicare Kien Giang Joint Stock Company	3,500,000,000	3,500,000,000
Famicare Hung Yen Joint Stock Company	-	3,500,000,000
Golab Quang Ngai Testing Center Joint Stock Company	1,677,000,000	3,500,000,000
Mr, Dang Vu Toan	-	1,000,000,000
Golab Ca Mau Test Center Joint Stock Company	1,138,000,000	-
<i>Receivables from Other Organizations and Individuals (*)</i>	<b>62,993,050,000</b>	<b>47,600,000,000</b>
Công ty Cổ phần Sara Việt Nam	20,651,000,000	-
G7 High Technology Joint Stock Company	22,000,000,000	22,000,000,000
Vietnam-Japan Production Linkage Joint Stock Company	13,500,000,000	13,500,000,000
Vinam Sai Gon Company Limited	1,000,000,000	1,000,000,000
Ha Long Tokyo Medical and Environmental High-Tech Joint Stock Company	5,842,050,000	11,100,000,000
<b>Total</b>	<b>70,808,050,000</b>	<b>62,850,000,000</b>

(\*) These are capital support advances which have not been recovered up to the reporting date..

**AMERICAN VIETNAMESE BIOTECH INCORPORATION**

Address: 4th Floor, Phu Ma Duong Building, No. 85 Hoang Van Thai Street, Tan My Ward, Ho Chi Minh City, Vietnam

For the six-month period of the financial year ending 31 December 2025

**Notes to the Interim Consolidated Financial Statements (continued)****6. Other receivables****a. Other Short-term Receivables**

	Ending balance		Beginning balance	
	Value	Provision	Value	Provision
<i>Receivables From Related Parties</i>	<b>60,746,575</b>	-	<b>9,414,521</b>	-
Capital Support Interest – Famicare Long An Joint Stock Company	-	-	9,414,521	-
Capital Support Interest – Famicare Kien Giang Joint Stock Company	60,746,575	-	-	-
<i>Receivables From Other Organizations And Individuals</i>	<b>330,772,579,690</b>	<b>(42,192,780,000)</b>	<b>4,929,326,456</b>	-
Advances To Employees And Other Parties	281,208,975	-	349,314,844	-
Deposits And Guarantees	1,284,480,893	-	981,485,523	-
Interest Receivable From Loans To Third Parties	1,121,096,746	-	616,091,884	-
Obstetrics And Pediatrics Center – Phu Tho Provincial General Hospital (1)	43,500,000,000	-	-	-
Hoa Binh Agricultural Machinery Investment Joint Stock Company (2)	85,669,000,000	(17,994,000,000)	-	-
Sara Hospital Investment Joint Stock Company (2)	33,566,000,000	(7,669,800,000)	-	-
Can Tho Investment High Tech Joint Stock Company (2)	30,727,000,000	(5,966,100,000)	-	-
Can Tho Environment And Test Center Joint Stock Company (2)	11,629,500,000	(2,820,000,000)	-	-
High-Tech Medical Environment Company Limited (2)	45,560,000,000	-	-	-
Nhat Medical Equipment Company Limited (2)	39,312,000,000	-	-	-
Lou Investment Joint Stock Company (2)	35,079,000,000	(7,687,800,000)	-	-
Hung Dai Viet Container Company Limited	110,160,000	(55,080,000)	-	-
Other Receivables	2,933,133,076	-	2,982,434,205	-
<b>Total</b>	<b>330,833,326,265</b>	<b>(42,192,780,000)</b>	<b>4,938,740,977</b>	-

(2) These are advance payments made for the purchase of machinery, software, and medical equipment to serve the Company's business operations. However, as the delivery period has expired, the parties have agreed to cancel the contracts and refund the payments. As of the reporting date, the outstanding advances that have not yet been recovered amounted to VND 208,603,170,000.

**b. Other Long-term Receivables**

	Ending balance		Beginning balance	
	Value	Provision	Value	Provision
<i>Receivables from Other Organizations and Individuals</i>	<b>211,142,000,000</b>	-	<b>61,988,000,000</b>	-
Deposits and Guarantees	198,000,000	-	271,000,000	-
Sara Vung Tau Joint Stock Company (3)	61,717,000,000	-	61,717,000,000	-
Obstetrics and Pediatrics Center – Phu Tho Provincial General Hospital (1)	149,227,000,000	-	-	-
<b>Total</b>	<b>211,142,000,000</b>	-	<b>61,988,000,000</b>	-



**AMERICAN VIETNAMESE BIOTECH INCORPORATION**

Address: 4th Floor, Phu Ma Duong Building, No. 85 Hoang Van Thai Street, Tan My Ward, Ho Chi Minh City, Vietnam

For the six-month period of the financial year ending 31 December 2025

**Notes to the Interim Consolidated Financial Statements (continued)**

---

(1) Under Contract No. 01/2025/HĐCN/SARA-VIETMY dated February 15, 2025, the Company acquired the capital contribution of Sara Vietnam Joint Stock Company in Phu Tho Provincial General Hospital for the purpose of investing in the construction of the Obstetrics and Pediatrics Center of Phu Tho Provincial General Hospital, with a transfer value of VND 204,227,000,000.

However, pursuant to Resolution of the Board of Directors No. 1604/2025/NQ-BOD dated April 16, 2025, the Company resolved to withdraw its investment in Phu Tho Obstetrics and Pediatrics Hospital ahead of schedule. On April 21, 2025, the Company and the Hospital signed Annex No. 05 to the contract regarding the early withdrawal of capital. Accordingly, the Hospital will refund the Company's contributed capital in installments from 2025 to 2028. As of the date of issuance of this report, the Hospital has reimbursed the Company VND 17.5 billion.

(3) This represents a joint investment between Viet My Hospital Investment Joint Stock Company (Party A) and Sara Vung Tau Joint Stock Company (Party B) under Joint Investment Contract No. 11.12.2020/SRVT-BVVM dated December 11, 2020 regarding the 'Investment in the Centralized Medical Waste Treatment Facility Project' with a provisional total investment value of VND 123,434,000,000, of which the Company contributed an amount equivalent to 50% of the investment value. The investment contract term is 10 years from the date of signing by both parties.

According to Decision No. 2830/QĐ-UBND dated October 29, 2024 of the People's Committee of Ba Ria – Vung Tau Province approving the adjustment of the investment policy and investor, the project schedule was revised as follows: 'Phase 1: Carry out investment and construction procedures, install equipment for trial operation, and put the project into official operation within 09 months from the date of the decision on the adjustment of the investment policy.'

As of the reporting date, the project has not yet commenced operations and is still under implementation by the parties.

**AMERICAN VIETNAMESE BIOTECH INCORPORATION**

Address: 4th Floor, Phu Ma Duong Building, No. 85 Hoang Van Thai Street, Tan My Ward, Ho Chi Minh City, Vietnam

For the six-month period of the financial year ending 31 December 2025

**Notes to the Interim Consolidated Financial Statements (continued)**

**7. Doubtful debts**

	Ending balance		Overdue Period	Beginning balance	
	Overdue Period	Value	Provision	Value	Provision
<b>Trade Receivables From Customers</b>		<b>141,855,328,713</b>	<b>(42,821,038,204)</b>	<b>1,867,167,534</b>	<b>(1,801,022,208)</b>
Thanh Ha Technical Company Limited	Recovered	-	-	1,352,357,988	(1,352,357,988)
Lou Investment Joint Stock Company	Overdue From 6 Months To Less Than 1 Year	809,943,585	(242,983,076)	-	-
Hoa Binh Agricultural Machinery Investment Joint Stock Company	Overdue From 6 Months To Less Than 1 Year	59,980,000,000	(17,994,000,000)	-	-
Dai Viet Container Company Limited	Overdue From 1 Year To Less Than 2 Years	110,160,000	(55,080,000)	-	-
Can Tho Environment And Test Center Joint Stock Company	Overdue From 1 Year To Less Than 2 Years	9,400,000,000	(2,820,000,000)	-	-
Sara Hospital Investment Joint Stock Company	Overdue From 6 Months To Less Than 1 Year	25,566,000,000	(7,669,800,000)	-	-
Can Tho Investment High Tech Joint Stock Company	Overdue From 6 Months To Less Than 1 Year	19,887,000,000	(5,966,100,000)	-	-
Lou Investment Joint Stock Company	Overdue From 6 Months To Less Than 1 Year	25,626,000,000	(7,687,800,000)	-	-
Others		476,225,128	(385,275,128)	514,809,546	(448,664,220)
<b>Prepayments To Suppliers</b>		<b>14,442,500,000</b>	<b>(7,221,250,000)</b>	<b>41,186,000,000</b>	<b>(20,593,000,000)</b>
High-Tech Medical Environment Company Limited	Overdue From 1 Year To Less Than 2 Years	8,672,000,000	(4,336,000,000)	17,186,000,000	(8,593,000,000)
Can Tho Laboratory And Environment Center Joint Stock Company	Overdue From 1 Year To Less Than 2 Years	5,770,500,000	(2,885,250,000)	24,000,000,000	(12,000,000,000)
<b>Total</b>		<b>156,297,828,713</b>	<b>(50,042,288,204)</b>	<b>43,053,167,534</b>	<b>(22,394,022,208)</b>

The movement of the provision for doubtful receivables and loans is as follows:

	Short-term Receivables and Loans Receivable	Long-term Receivables and Loans Receivable	Total
Beginning balance	(22,394,022,208)	-	(22,394,022,208)
Additional Provision Made	(27,648,265,996)	-	(27,648,265,996)
<b>Ending balance</b>	<b>(50,042,288,204)</b>	<b>-</b>	<b>(50,042,288,204)</b>



**AMERICAN VIETNAMESE BIOTECH INCORPORATION**

Address: 4th Floor, Phu Ma Duong Building, No. 85 Hoang Van Thai Street, Tan My Ward, Ho Chi Minh City, Vietnam

For the six-month period of the financial year ending 31 December 2025

**Notes to the Interim Consolidated Financial Statements (continued)****8. Inventories**

	Ending balance		Beginning balance	
	Cost	Provision	Cost	Provision
Raw materials	1,307,843,773	-	887,196,782	-
Tools and instruments	251,158,491	-	230,158,491	-
Finished goods	-	-	2,432,186	-
Final goods	66,161,791,647	-	47,964,265,318	-
<b>Total</b>	<b>67,720,793,911</b>	<b>-</b>	<b>49,084,052,777</b>	<b>-</b>

**9. Prepaid expenses****a. Short-term prepaid expenses**

	Ending balance	Beginning balance
Office Rental Expenses	34,222,222	31,111,111
Repair and Maintenance Expenses	-	3,472,225
Tools and Supplies	61,323,218	121,392,793
Other Short-term Prepaid Expenses	16,261,273	26,403,033
<b>Total</b>	<b>111,806,713</b>	<b>182,379,162</b>

**b. Long-term prepaid expenses**

	Ending balance	Beginning balance
Land Lease Expenses	1,226,925,085	1,242,010,229
Staff Training Expenses	1,012,164,693	1,168,443,977
Tools and Supplies	42,958,501	64,599,976
Other Long-term Prepaid Expenses	480,435,249	49,286,865
<b>Total</b>	<b>2,762,483,528</b>	<b>2,524,341,047</b>

**AMERICAN VIETNAMESE BIOTECH INCORPORATION**

Address: 4th Floor, Phu Ma Duong Building, No. 85 Hoang Van Thai Street, Tan My Ward, Ho Chi Minh City, Vietnam

For the six-month period of the financial year ending 31 December 2025

**Notes to the Interim Consolidated Financial Statements (continued)****10. Tangible Fixed Assets**

	<b>Buildings and structures</b>	<b>Machinery and Equipment</b>	<b>Transport and Transmission Vehicles</b>	<b>Total</b>
<b>Historical cost</b>				
Beginning balance	10,894,525,377	209,066,380,825	244,540,000	220,205,446,202
Completed completed capital construction	-	4,030,000,000	-	4,030,000,000
Disposal, sale	-	(352,200,000)	-	(352,200,000)
<b>Ending balance</b>	<b>10,894,525,377</b>	<b>212,744,180,825</b>	<b>244,540,000</b>	<b>223,883,246,202</b>
<i>Including:</i>				
<i>Fully depreciated but still in use</i>	-	7,392,200,000	244,540,000	7,636,740,000
<b>Depreciation value</b>				
Beginning balance	1,154,886,543	51,846,313,658	230,899,649	53,232,099,850
Depreciation in year	330,545,658	10,611,298,675	13,640,351	10,955,484,684
Disposal, sale	-	(352,200,000)	-	(352,200,000)
<b>Ending balance</b>	<b>1,485,432,201</b>	<b>62,105,412,333</b>	<b>244,540,000</b>	<b>63,835,384,534</b>
<b>Net Book Value</b>				
Beginning balance	9,739,638,834	157,220,067,167	13,640,351	166,973,346,352
<b>Ending balance</b>	<b>9,409,093,176</b>	<b>150,638,768,492</b>	<b>-</b>	<b>160,047,861,668</b>

Certain tangible fixed assets in the form of machinery and equipment, with historical cost and net book value of VND 146,495,236,103 and VND 106,092,288,843, respectively, have been pledged as collateral for loans at Viet Capital Commercial Joint Stock Bank and Viet A Commercial Joint Stock Bank – Hoang Mai Branch (Note V.18).

**11. Intangible Fixed Assets**

	<b>Software Program</b>	<b>Total</b>
<b>Historical Cost</b>		
Beginning balance	149,316,480,623	149,316,480,623
Decrease due to divestment	(616,034,286)	(616,034,286)
<b>Ending balance</b>	<b>148,700,446,337</b>	<b>148,700,446,337</b>
<b>Depreciation value</b>		
Beginning balance	26,794,782,453	26,794,782,453
Depreciation in year	5,924,599,230	5,924,599,230
Decrease due to divestment	(479,738,698)	(479,738,698)
<b>Ending balance</b>	<b>32,239,642,985</b>	<b>32,239,642,985</b>
<b>Net Book Value</b>		
Beginning balance	122,521,698,170	122,521,698,170
<b>Ending balance</b>	<b>116,460,803,352</b>	<b>116,460,803,352</b>

+ The Company's intangible fixed assets consist of software programs, including:

- Management software system
- PACS software system (\*)

(\*) This is the RIS-PACS medical imaging storage and transmission system that the Company has installed in an integrated manner to support medical examination, treatment, and diagnostic imaging, together with accompanying hardware installed at medical facilities (general hospitals and provincial/city medical centers) under cooperation agreements for pilot use or business cooperation



**AMERICAN VIETNAMESE BIOTECH INCORPORATION**

Address: 4th Floor, Phu Ma Duong Building, No. 85 Hoang Van Thai Street, Tan My Ward, Ho Chi Minh City, Vietnam

For the six-month period of the financial year ending 31 December 2025

**Notes to the Interim Consolidated Financial Statements (continued)**

between the Company and such medical facilities. The system has been accepted and handed over by the medical facilities for official operation..

At certain hospitals, revenue has been generated; however, due to the absence of specific and consistent guidelines on the settlement of diagnostic imaging services based on the PACS system, the Company does not yet have a reliable basis to fully determine the economic benefits to be derived from these leasing and business cooperation arrangements. Currently, the Company mainly charges fees for the provision of maintenance and servicing of machinery and equipment, as well as 24/7 technical support for the PACS system.

+ Certain intangible fixed assets in the form of software programs, with historical cost and net book value of VND 36,639,885,600 and VND 31,456,623,942, respectively, have been pledged as collateral for the bond issuance at Viet A Commercial Joint Stock Bank – Hoang Mai Branch (Note V.18).

**12. Construction in progress**

	<b>Beginning balance</b>	<b>Incurred During the Year</b>	<b>Transferred to Fixed Assets</b>	<b>Transferred to Inventories for Sale</b>	<b>Ending balance</b>
Purchases	27,466,646,084	8,799,214,562	(4,030,000,000)	(3,513,570,000)	28,722,290,646
<i>Hardware and Software Systems at Hospitals</i>	6,227,155,144	8,799,214,562	(4,030,000,000)	(3,513,570,000)	7,482,799,706
<i>PACS Systems at Medical Centers</i>	21,239,490,940	-	-	-	21,239,490,940
<b>Total</b>	<b>27,466,646,084</b>	<b>8,799,214,562</b>	<b>(4,030,000,000)</b>	<b>(3,513,570,000)</b>	<b>28,722,290,646</b>

# AMERICAN VIETNAMESE BIOTECH INCORPORATION

Address: 4th Floor, Phu Ma Duong Building, No. 85 Hoang Van Thai Street, Tan My Ward, Ho Chi Minh City, Vietnam

For the six-month period of the financial year ending 31 December 2025

## Notes to the Interim Consolidated Financial Statements (continued)

### 13. Financial investments

#### a. Investments in joint-ventures, associates

These are investments in a network of associates established to set up clinics and testing centers across the country. Details of the investments as at June 30, 2025 are as follows:

	Ending balance			Beginning balance		
	Cost	Ownership Interest (%)	Consolidated Value	Cost	Ownership Interest (%)	Consolidated Value
<i>Investment in Associates</i>	<i>724,839,500,000</i>		<i>720,324,855,375</i>	<i>623,720,000,000</i>		<i>621,833,841,759</i>
Golab Phap Van Test Center Joint Stock Company	10,500,000,000	35%	10,414,377,985	10,500,000,000	35%	10,468,660,741
Famicare Phap Van Joint Stock Company (*)	10,500,000,000	35%	10,500,000,000	10,500,000,000	35%	10,487,344,633
Golab Go Vap Laboratory Center Joint Stock Company	10,500,000,000	35%	10,436,649,594	10,500,000,000	35%	10,470,876,879
Nghe An Clinic Joint Stock Company	10,500,000,000	35%	10,430,282,187	10,500,000,000	35%	10,464,121,805
Ba Dinh Clinic Joint Stock Company (*)	10,500,000,000	35%	9,929,033,277	10,500,000,000	35%	10,040,962,452
Golab Bac Lieu Test Center Joint Stock Company	10,500,000,000	35%	10,425,519,035	10,500,000,000	35%	10,466,242,827
Golab Tien Giang Test Center Joint Stock Company	10,500,000,000	35%	10,462,288,060	10,500,000,000	35%	10,477,542,900
Golab Binh Duong Laboratory Center Joint Stock Company (*)	10,500,000,000	35%	10,440,009,626	10,500,000,000	35%	10,487,593,716
Famicare Tuyen Quang Joint Stock Company	10,500,000,000	35%	10,468,536,193	10,500,000,000	35%	10,484,816,912
Golab Ha Giang Diagnostic Center Joint Stock Company	14,700,000,000	49%	14,658,334,958	14,700,000,000	49%	14,696,251,303
Huu Nghi Medicare Clinic Joint Stock Company	14,700,000,000	49%	14,561,803,439	14,700,000,000	49%	14,583,313,003
Golab Ninh Binh Test Center Joint Stock Company	14,700,000,000	49%	14,571,929,341	14,700,000,000	49%	14,633,793,339
Golab Vung Tau Laboratory Center Joint Stock Company (*)	14,700,000,000	49%	14,534,435,617	14,700,000,000	49%	14,616,734,451
Famicare Hung Yen Joint Stock Company (*)	10,500,000,000	35%	10,450,701,047	10,500,000,000	35%	10,480,619,641
Golab Dong Thap Diagnostic Center Joint Stock Company	10,500,000,000	35%	10,468,872,231	10,500,000,000	35%	10,481,368,892
Golab Ben Tre Test Center Joint Stock Company (*)	7,330,000,000	24%	7,308,731,201	-	25%	-
Golab Kon Tum Diagnostic Center Joint Stock Company (*)	13,500,000,000	45%	13,465,934,384	13,500,000,000	45%	13,491,265,681
Golab District 5 Diagnostic Center Joint Stock Company (*)	10,500,000,000	35%	10,411,068,629	10,500,000,000	35%	10,473,166,161
Golab Quang Ngai Diagnostic Center Joint Stock Company (*)	10,500,000,000	35%	10,474,955,087	10,500,000,000	35%	10,496,772,207



**AMERICAN VIETNAMESE BIOTECH INCORPORATION**

Address: 4th Floor, Phu Ma Duong Building, No. 85 Hoang Van Thai Street, Tan My Ward, Ho Chi Minh City, Vietnam

For the six-month period of the financial year ending 31 December 2025

**Notes to the Interim Consolidated Financial Statements (continued)**

	Ending balance			Beginning balance		
	Cost	Ownership Interest (%)	Consolidated Value	Cost	Ownership Interest (%)	Consolidated Value
Golab Binh Thuan Test Center Joint Stock Company (*)	6,876,000,000	23%	6,854,410,801	-	49%	-
Golab Tay Ninh Diagnostic Center Joint Stock Company (*)	13,500,000,000	45%	13,451,988,590	13,500,000,000	45%	13,487,291,944
Golab Yen Bai Test Center Joint Stock Company (*)	7,388,000,000	25%	7,344,438,390	-	49%	-
Famicare Quang Binh Joint Stock Company (*)	10,500,000,000	35%	10,452,645,428	10,500,000,000	35%	10,488,594,697
Golab Hung Yen Test Center Joint Stock Company	10,500,000,000	35%	10,451,176,762	10,500,000,000	35%	10,479,265,174
Famicare Vinh Phuc Joint Stock Company (*)	4,900,000,000	49%	4,883,137,956	4,900,000,000	49%	4,895,828,523
Golab Ha Tinh Test Center Joint Stock Company	10,500,000,000	35%	10,408,774,434	10,500,000,000	35%	10,472,375,463
Golab Tuyen Quang Test Center Joint Stock Company	10,500,000,000	35%	10,440,476,264	10,500,000,000	35%	10,478,629,873
Golab Cao Bang Test Center Joint Stock Company	6,054,000,000	20%	6,047,394,966	-	-	-
Famicare Bac Ninh Joint Stock Company (*)	4,500,000,000	45%	4,467,548,805	4,500,000,000	45%	4,486,060,921
Famicare Hai Phong Joint Stock Company (*)	4,500,000,000	45%	4,455,056,045	4,500,000,000	45%	4,479,791,835
Famicare Ninh Binh Joint Stock Company (*)	4,500,000,000	45%	4,423,235,492	4,500,000,000	45%	4,466,503,284
Golab Gia Lai Diagnostic Center Joint Stock Company	14,400,000,000	48%	14,324,307,569	14,400,000,000	48%	14,371,903,783
Famicare Huu Nghi Joint Stock Company (*)	4,900,000,000	49%	4,876,034,022	4,900,000,000	49%	4,896,232,561
Famicare Gia Lai Joint Stock Company (*)	4,900,000,000	49%	4,878,434,660	4,900,000,000	49%	4,894,865,208
Famicare Hoa Binh Joint Stock Company (*)	4,800,000,000	48%	4,777,648,976	4,800,000,000	48%	4,777,648,976
Famicare Ha Tinh Joint Stock Company (*)	4,500,000,000	45%	4,453,702,313	4,500,000,000	45%	4,478,994,381
Famicare Nghe An Joint Stock Company (*)	4,500,000,000	45%	4,470,291,523	4,500,000,000	45%	4,487,138,584
Famicare Quang Ngai Joint Stock Company (*)	4,800,000,000	48%	4,780,280,924	4,800,000,000	48%	4,795,320,941
Golab Da Nang Diagnostic Center Joint Stock Company	13,500,000,000	45%	13,371,812,103	13,500,000,000	45%	13,455,589,423
Golab Vinh Yen Diagnostic Center Joint Stock Company (*)	14,700,000,000	49%	14,623,344,957	14,250,000,000	49%	14,247,745,702
Golab Bac Giang Test Center Joint Stock Company	7,384,000,000	25%	7,381,050,070	-	-	-
Famicare Tay Ninh Joint Stock Company (*)	4,900,000,000	49%	4,861,449,943	4,900,000,000	49%	4,892,326,736
Golab Hai Duong Diagnostic Center Joint Stock Company	10,500,000,000	35%	10,441,235,133	10,500,000,000	35%	10,468,641,283
Golab Quang Tri Diagnostic Center Joint Stock Company (*)	7,520,000,000	25%	7,485,521,826	6,170,000,000	51%	6,166,490,736



**AMERICAN VIETNAMESE BIOTECH INCORPORATION**

Address: 4th Floor, Phu Ma Duong Building, No. 85 Hoang Van Thai Street, Tan My Ward, Ho Chi Minh City, Vietnam

For the six-month period of the financial year ending 31 December 2025

**Notes to the Interim Consolidated Financial Statements (continued)**

	Ending balance			Beginning balance		
	Cost	Ownership Interest (%)	Consolidated Value	Cost	Ownership Interest (%)	Consolidated Value
Famicare Kontum Joint Stock Company (*)	4,900,000,000	49%	4,876,003,472	4,900,000,000	49%	4,892,624,948
Golab Dien Bien Test Center Joint Stock Company	14,400,000,000	48%	14,363,204,123	-	-	-
Golab Dak Nong Test Center Joint Stock Company	9,130,000,000	30%	9,111,760,404	-	-	-
Golab Bac Ninh Diagnostic Center Joint Stock Company	10,500,000,000	35%	10,463,949,268	10,500,000,000	35%	10,485,892,531
Golab Hai Phong Diagnostic Center Joint Stock Company	10,500,000,000	35%	10,243,889,459	10,500,000,000	35%	10,485,554,340
Famicare Binh Dinh Joint Stock Company (*)	4,800,000,000	48%	4,767,939,805	4,800,000,000	48%	4,788,337,829
Famicare 3/2 Joint Stock Company (*)	4,800,000,000	48%	4,800,000,000	4,800,000,000	48%	4,772,085,061
Famicare Soc Trang Joint Stock Company (*)	4,800,000,000	48%	4,784,502,294	4,800,000,000	48%	4,795,509,028
Golab Binh Dinh Diagnostic Center Joint Stock Company	14,400,000,000	48%	14,338,318,791	14,400,000,000	48%	14,373,372,434
Golab Dak Lak Test Center Joint Stock Company (*)	14,700,000,000	49%	14,663,622,129	14,700,000,000	49%	14,695,880,371
Golab Son La Test Center Joint Stock Company	8,862,000,000	30%	8,849,673,838	-	-	-
Famicare Dong Nai Joint Stock Company	3,500,000,000	35%	3,439,356,107	3,500,000,000	35%	3,481,662,069
Golab Tan An Laboratory Center Joint Stock Company (*)	10,500,000,000	35%	10,449,668,842	10,500,000,000	35%	10,474,872,804
Famicare Da Nang Joint Stock Company	4,500,000,000	45%	4,413,547,849	4,500,000,000	45%	4,466,161,771
Golab Phap Van Test Center Joint Stock Company (*)	6,400,000,000	21%	6,349,973,234	6,400,000,000	22%	6,367,284,424
Golab Ca Mau Test Center Joint Stock Company	14,700,000,000	49%	14,682,944,547	-	-	-
Famicare Hai Duong Joint Stock Company	10,500,000,000	35%	10,449,126,054	10,500,000,000	35%	10,486,390,188
Golab Quang Binh Diagnostic Center Joint Stock Company	10,500,000,000	35%	10,435,664,378	10,500,000,000	35%	10,482,294,599
Golab Vinh Phuc Diagnostic Center Joint Stock Company	10,500,000,000	35%	10,447,502,450	10,500,000,000	35%	10,476,494,908
Famicare Nam Dinh Joint Stock Company	4,900,000,000	49%	4,891,570,455	-	-	-
Famicare Vinh Long Joint Stock Company (*)	10,500,000,000	35%	10,462,249,257	10,500,000,000	35%	10,481,676,151
Golab Kien Giang Diagnostic Center Joint Stock Company	10,500,000,000	35%	10,456,906,496	10,500,000,000	35%	10,478,841,387
Famicare Bac Lieu Joint Stock Company (*)	10,500,000,000	35%	10,458,977,073	10,500,000,000	35%	10,479,389,170
Famicare Go Vap Joint Stock Company (*)	4,800,000,000	48%	4,747,146,913	4,800,000,000	48%	4,783,696,690



**AMERICAN VIETNAMESE BIOTECH INCORPORATION**

Address: 4th Floor, Phu Ma Duong Building, No. 85 Hoang Van Thai Street, Tan My Ward, Ho Chi Minh City, Vietnam

For the six-month period of the financial year ending 31 December 2025

**Notes to the Interim Consolidated Financial Statements (continued)**

	Ending balance			Beginning balance		
	Cost	Ownership Interest (%)	Consolidated Value	Cost	Ownership Interest (%)	Consolidated Value
Famicare Long An Joint Stock Company (*)	4,900,000,000	49%	4,877,601,494	4,900,000,000	49%	4,896,875,460
Famicare District 5 Joint Stock Company (*)	4,900,000,000	49%	4,857,859,172	4,900,000,000	49%	4,888,893,337
Famicare Ca Mau Joint Stock Company	4,900,000,000	26%	4,882,713,024	-	-	-
Famicare Son La Joint Stock Company	2,612,500,000	49%	2,591,626,934	-	-	-
Golab Tra Vinh Diagnostic Center Joint Stock Company	10,500,000,000	35%	10,452,627,622	10,500,000,000	35%	10,468,924,313
Golab An Giang Diagnostic Center Joint Stock Company	10,500,000,000	35%	10,425,203,274	10,500,000,000	35%	10,461,792,501
Famicare Kien Giang Joint Stock Company (*)	10,500,000,000	35%	10,437,145,385	10,500,000,000	35%	10,479,918,162
Famicare An Giang Joint Stock Company (*)	4,900,000,000	49%	4,877,277,061	4,900,000,000	49%	4,895,253,645
Famicare Thu Dau Mot Joint Stock Company (*)	4,900,000,000	49%	4,881,199,945	4,900,000,000	49%	4,895,253,635
Famicare Dong Thap Joint Stock Company (*)	4,900,000,000	49%	4,882,474,308	4,900,000,000	49%	4,896,689,689
Famicare Tien Giang Joint Stock Company (*)	4,900,000,000	49%	4,877,294,712	4,900,000,000	49%	4,896,381,307
Famicare Tra Vinh Joint Stock Company (*)	4,900,000,000	49%	4,870,999,726	4,900,000,000	49%	4,895,253,645
Golab Bien Hoa Laboratory Center Joint Stock Company	10,500,000,000	35%	10,413,769,206	10,500,000,000	35%	10,460,334,999
Golab Vinh Long Diagnostic Center Joint Stock Company	10,500,000,000	35%	10,460,385,986	10,500,000,000	35%	10,481,562,792
Famicare Quang Nam Joint Stock Company	4,783,000,000	48%	4,770,320,445	-	-	-
<b>Total</b>	<b>724,839,500,000</b>		<b>720,324,855,375</b>	<b>623,720,000,000</b>		<b>621,833,841,759</b>

(\*) These associates have been established but have not yet formed, or possess insignificant, assets to support business operations.

**AMERICAN VIETNAMESE BIOTECH INCORPORATION**

Address: 4th Floor, Phu Ma Duong Building, No. 85 Hoang Van Thai Street, Tan My Ward, Ho Chi Minh City, Vietnam

For the six-month period of the financial year ending 31 December 2025

Notes to the Interim Consolidated Financial Statements (continued)

**b, Other Investments**

	Ending balance		Beginning balance	
	Cost	Ownership Interest (%)	Consolidated Value	Cost
<b>Other Investments</b>	<b>14,658,000,000</b>	<b>(44,664,050)</b>	<b>14,613,335,950</b>	-
Famicare Binh Phuoc Joint Stock Company	100,000,000	(891,773)	99,108,227	-
Famicare Ben Tre Joint Stock Company	100,000,000	(881,495)	99,118,505	-
Famicare Hue Joint Stock Company	200,000,000	-	200,000,000	-
Golab Binh Phuoc Test Center Joint Stock Company	1,021,000,000	(329,315)	1,020,670,685	-
Golab Ben Tre Test Center Joint Stock Company	600,000,000	-	600,000,000	-
Golab Thai Binh Test Center Joint Stock Company	4,337,000,000	(31,636,565)	4,305,363,435	-
Golab Lang Son Test Center Joint Stock Company	4,400,000,000	(7,412,037)	4,392,587,963	-
Golab Hue Test Center Joint Stock Company	1,200,000,000	(806,868)	1,199,193,132	-
Golab Binh Thuan Test Center Joint Stock Company	2,700,000,000	(2,705,997)	2,697,294,003	-
<b>Total</b>	<b>14,658,000,000</b>	<b>(44,664,050)</b>	<b>14,613,335,950</b>	-



**AMERICAN VIETNAMESE BIOTECH INCORPORATION**

Address: 4th Floor, Phu Ma Duong Building, No. 85 Hoang Van Thai Street, Tan My Ward, Ho Chi Minh City, Vietnam

For the six-month period of the financial year ending 31 December 2025

**Notes to the Interim Consolidated Financial Statements (continued)**

**14. Short-term trade receivables**

	<b>Ending balance</b>	<b>Beginning balance</b>
<i>Payables to Other Suppliers</i>	<b>25,279,812,907</b>	<b>15,246,276,978</b>
Hong Anh Technique Company Limited	5,121,859,377	5,925,908,591
Japan Kanpeki Joint Stock Company	2,077,293,438	1,782,456,736
Aiko International Group Joint Stock Company	4,725,000,000	4,725,000,000
VINAM JOINT STOCK COMPANY	10,673,250,000	-
Other Suppliers	2,682,410,092	2,812,911,651
<b>Total</b>	<b>25,279,812,907</b>	<b>15,246,276,978</b>

**15. Taxes and amounts payable to the State**

	Beginning balance		Arising during the year			Ending balance	
	Payables	Receivables	Payable in year	Paid in year	Adjustment for misclassification of sub-item	Payables	Receivables
VAT on imported goods	1,387,349,718	2,446,143	261,939,176	(981,402,031)	(200,000,000)	465,440,720	-
Corporate income tax (CIT)	1,574,596,828	200,000,000	342,276,614	-	200,000,000	1,916,873,442	-
Personal income tax (PIT)	176,589,749	674,604	229,769,196	(139,833,276)	-	186,225,796	888,89
Other taxes	-	3,000,000	95,397,815	(95,397,815)	-	-	3,000,000
Total	3,138,536,295	206,120,747	929,382,801	(1,216,633,122)	-	2,568,539,958	3,888,890

The Company's tax settlement will be subject to inspection by tax authorities. Because the application of tax laws and regulations to many different types of transactions can be interpreted in different ways, the tax amount presented in the Financial Statements is subject to change at the discretion of the competent tax authorities.

**Value-added tax**

The company pays value-added tax according to the deduction method. The applicable Value Added Tax (VAT) rates are as follows:

- Revenue from the sale of medical supplies and equipment 5%
- Revenue from diagnostic and imaging services provided in collaboration with hospitals Not Subject to VAT
- Other business activities 8%, 10%

**AMERICAN VIETNAMESE BIOTECH INCORPORATION**

Address: 4th Floor, Phu Ma Duong Building, No. 85 Hoang Van Thai Street, Tan My Ward, Ho Chi Minh City, Vietnam

For the six-month period of the financial year ending 31 December 2025

**Notes to the Interim Consolidated Financial Statements (continued)****Corporate income tax**

The following subsidiaries: Medicare Hau Giang Clinic Joint Stock Company, Medicare Soc Trang Clinic Joint Stock Company, Medicare Nga Bay Clinic Joint Stock Company, and Song Hau New Technology Application Research Joint Stock Company are operating in areas with difficult or especially difficult socio-economic conditions.

In accordance with Point a, Clause 1, Article 15 and Point a, Clause 1, Article 16 of Decree No. 218/2013/NĐ-CP dated 26 December 2013 of the Government, which provides guidance on the implementation of the Law on Corporate Income Tax, as amended and supplemented under Clause 16, Article 1 of Decree No. 12/2015/NĐ-CP dated 12 February 2015, these entities are entitled to the following corporate income tax incentives:

- Exemption from corporate income tax for 4 years (from 2021 to 2024);
- 50% reduction of corporate income tax payable for the subsequent 9 years (from 2025 to 2033);
- Application of a preferential tax rate of 10% for a period of 15 years starting from 2021.

Other business activities of the Company are subject to corporate income tax at the standard rate of 20%.

**Other taxes**

The company has declared and paid these taxes in line with the prevailing regulations.

**16. Accrued expenses****a. Short-term accrued expenses**

	<b>Ending balance</b>	<b>Beginning balance</b>
Accrued Interest Expenses	21,770,309,214	19,426,244,808
Accrued Bond Interest Payable	6,798,650,281	7,965,091,377
Others	123,504,109	2,353,340,456
<b>Total</b>	<b>28,692,463,604</b>	<b>29,744,676,641</b>

**b. Long-term accrued expenses**

	<b>Ending balance</b>	<b>Beginning balance</b>
Accrued Land Lease Expenses	337,798,283	337,798,283
<b>Total</b>	<b>337,798,283</b>	<b>337,798,283</b>

**17. Other short-term payables**

	<b>Ending balance</b>	<b>Beginning balance</b>
<b>Payables to Other Entities and Individuals</b>	<b>76,821,080,861</b>	<b>78,118,781,977</b>
Social Insurance	110,235,000	-
Health Insurance	19,842,300	-
Unemployment Insurance	8,818,800	-
Dividends Payable for 2019 (*)	75,924,090,000	75,924,090,000
Other Dividends Payable	748,710,561	2,187,486,071
Occupational Accident and Occupational Disease Insurance	2,204,200	-
Other Current Payables	7,180,000	7,205,906
<b>Total</b>	<b>76,821,080,861</b>	<b>78,118,781,977</b>



**AMERICAN VIETNAMESE BIOTECH INCORPORATION**

Address: 4th Floor, Phu Ma Duong Building, No. 85 Hoang Van Thai Street, Tan My Ward, Ho Chi Minh City, Vietnam

For the six-month period of the financial year ending 31 December 2025

**Notes to the Interim Consolidated Financial Statements (continued)**

(\*) The 2019 dividend payable to shareholders was determined based on the shareholder list as at January 12, 2021. Pursuant to Resolution No. 2502/NQ-BOD dated February 25, 2025 of the Board of Directors regarding the change in the timing of the 2019 dividend payment, the dividend will be paid as follows: First installment on January 28, 2026; Second installment on July 28, 2026.

Reason for the change: The Company is expanding its business operations and investing in equipment and machinery for key projects. To ensure project progress, the Company has utilized available funds to place orders for the necessary equipment.

**18. Loans and obligations under finance leases****a. Short-term loans and obligations under finance leases**

	Ending balance		Beginning balance	
	Value	Amount able to pay off	Value	Amount able to pay off
<b>Short-term Borrowings and Finance Lease Liabilities</b>				
<b>Payable to Related Parties</b>	<b>46,991,222</b>	<b>46,991,222</b>	<b>3,500,000,000</b>	<b>3,500,000,000</b>
Mrs Bui Thi Phuong Thao	-	-	1,680,000,000	1,680,000,000
Mr. Nguyen Hong Thanh	46,991,222	46,991,222	-	-
Mr Vu Hoang Chuong	-	-	1,820,000,000	1,820,000,000
<b>Short-term Borrowings and Finance Lease Liabilities</b>				
<b>Payable to Other</b>				
<b>Organizations and Individuals</b>	<b>149,626,095,827</b>	<b>149,626,095,827</b>	<b>24,625,095,827</b>	<b>24,625,095,827</b>
<b>Viet Capital Commercial Joint Stock Bank (1)</b>	<b>23,126,095,827</b>	<b>23,126,095,827</b>	<b>24,625,095,827</b>	<b>24,625,095,827</b>
Short-term Ordinary Bonds (2)	126,500,000,000	126,500,000,000	-	-
<b>Cộng</b>	<b>149,673,087,049</b>	<b>149,673,087,049</b>	<b>28,125,095,827</b>	<b>28,125,095,827</b>

(1) Loan under Credit Contract No. 0041900059900 dated November 28, 2019; Amendment and Supplement Agreement dated July 6, 2021 regarding the adjustment of the principal repayment schedule. Loan amount: VND 40,000,000,000; Purpose of loan: Purchase of medical machinery and equipment for business operations; Interest rate: 11.5% per annum; Loan term: 48 months. Collateral: medical machinery and equipment under Movable Asset Mortgage Contract No. 0041900060000 dated November 28, 2019.

As of the date of issuance of this report, the above loan was overdue for repayment. The request for loan extension was submitted by the Company under Official Letter No. 05/2024/CV-AMV in October 2024 and was approved by Viet Capital Commercial Joint Stock Bank under Official Letter No. 212/2024/BVbank/CV-QL&THN dated April 9, 2024. However, as of the reporting date, the Company had not fully settled the outstanding principal of the loan and is continuing to work with the Bank to request a further extension.

**AMERICAN VIETNAMESE BIOTECH INCORPORATION**

Address: 4th Floor, Phu Ma Duong Building, No. 85 Hoang Van Thai Street, Tan Ward, Ho Chi Minh City, Vietnam

For the six-month period of the financial year ending 31 December 2025

**Notes to the Interim Consolidated Financial Statements (continued)**

Details of short-term loans and obligations under finance leases are as follows:

	Beginning balance	Borrows in year	Transfer from long-term borrowings and debts	Paid in year	Ending balance
<b>Bank Loans</b>	24,625,095,827	-	-	(1,499,000,000)	23,126,095,827
Viet Capital Commercial Joint Stock Bank (1)	24,625,095,827	-	-	(1,499,000,000)	23,126,095,827
<b>Short-term Ordinary Bonds (2)</b>	-	-	126,500,000,000	-	126,500,000,000
<b>Loans from Related Individuals</b>	3,500,000,000	46,991,222	-	(3,500,000,000)	46,991,222
Mr. Nguyen Hong Thanh	-	46,991,222	-	-	46,991,222
Mrs Bui Thi Phuong Thao	1,680,000,000	-	-	(1,680,000,000)	-
Mr Vu Hoang Chuong	1,820,000,000	-	-	(1,820,000,000)	-
<b>Total</b>	<b>28,125,095,827</b>	<b>46,991,222</b>	<b>126,500,000,000</b>	<b>(4,999,000,000)</b>	<b>149,673,087,049</b>

**b. Long-term loans and obligations under finance leases**

	Ending balance		Beginning balance	
	Value	Amount able to pay off	Value	Amount able to pay off
Long-term Bonds (2)	-	-	126,500,000,000	126,500,000,000
Par Value of Ordinary Bonds	-	-	126,500,000,000	126,500,000,000
<b>Total</b>	<b>-</b>	<b>-</b>	<b>126,500,000,000</b>	<b>126,500,000,000</b>

(2) Viet My Hospital Investment Joint Stock Company issued private placement bonds with a par value of VND 100,000,000 per bond, bond code VMH12101.

The bonds have a maturity term of 60 months from the issuance date, with maturity on January 7, 2026. The fixed interest rate is 11% per annum, payable semi-annually. The Company successfully offered 1,350 bonds, equivalent to VND 135,000,000,000. On January 18, 2024, the Company redeemed 85 bonds upon maturity for certain bondholders who did not consent to the extension of the maturity date from January 7, 2024 to January 7, 2026. Accordingly, the number of bonds outstanding as at June 30, 2025 is 1,265 bonds.

The intended use of proceeds from the private bond issuance, according to Resolution of the General Meeting of Shareholders No. 29.1/2021/NQ-GMS-BVVM dated January 29, 2021, was as follows, with a projected total issuance value of VND 200,000,000,000:

- To supplement working capital for business operations: VND 96,735,400,000;
- To cooperate in the investment of the Spect system with Aiko International Joint Stock Company at Phu Tho Provincial General Hospital: VND 41,547,600,000;
- To cooperate in the investment in the Vung Tau Waste Treatment Project: VND 61,717,000,000 (details in Note V.6b).

According to Resolution No. 2307/2024/NQ-BOD of the Board of Directors dated July 23, 2024 regarding the change in the use of proceeds, the funds raised from the bond issuance as at July 23, 2024 amounted to VND 126,500,000,000 and were utilized as follows:

- To supplement working capital for business operations: VND 64,783,000,000;
- To cooperate in the investment in the Vung Tau Waste Treatment Project: VND 61,717,000,000.



**AMERICAN VIETNAMESE BIOTECH INCORPORATION**

Address: 4th Floor, Phu Ma Duong Building, No. 85 Hoang Van Thai Street, Tan My Ward, Ho Chi Minh City, Vietnam

For the six-month period of the financial year ending 31 December 2025

**Notes to the Interim Consolidated Financial Statements (continued)**

Collateral: Medical machinery and equipment currently in use by Aiko International Group Joint Stock Company; machinery and equipment in use under the IVF Testing Center Project in Phu Tho; and medical machinery and equipment currently in use at the Company..

Details of long-term loans and obligations under finance leases are as follows:

	<b>Beginning balance</b>	<b>Borrows in year</b>	<b>Transfer to short-term borrowings and finance leases</b>	<b>Paid in year</b>	<b>Ending balance</b>
Ordinary bonds	126,500,000,000	-	(126,500,000,000)	-	-
<b>Total</b>	<b>126,500,000,000</b>	<b>-</b>	<b>(126,500,000,000)</b>	<b>-</b>	<b>-</b>

**19. Owners's equity***a, Statement of fluctuations in owners's equity*

	<b>Owner's investment capital</b>	<b>Share premium</b>	<b>Retained earnings</b>	<b>Non-controlling interests</b>	<b>Total</b>
Beginning balance of the previous year	1,311,056,500,000	(395,300,000)	302,853,804,073	72,214,156,500	1,685,729,160,573
Profit in the previous year	-	-	(11,191,161,405)	(1,874,036,904)	(13,065,198,309)
Distribution of dividends and profits	-	-	-	(204,081,632)	(204,081,632)
Increase due to newly consolidated subsidiary	-	-	-	180,000,000	180,000,000
Decrease due to loss of control over a subsidiary	-	-	166,531,098	(96,601,406)	69,929,692
<b>Ending balance of the previous year</b>	<b>1,311,056,500,000</b>	<b>(395,300,000)</b>	<b>291,829,173,766</b>	<b>70,219,436,558</b>	<b>1,672,709,810,324</b>
Beginning balance of the current year	1,311,056,500,000	(395,300,000)	291,829,173,766	70,219,436,558	1,672,709,810,324
Profit during the year	-	-	(39,721,984,252)	(1,284,112,275)	(41,006,096,527)
Distribution of dividends and profits	-	-	-	(347,129,374)	(347,129,374)
Decrease due to loss of control over a subsidiary	-	-	-	(591,470,145)	(591,470,145)
<b>Ending balance of the current year</b>	<b>1,311,056,500,000</b>	<b>(395,300,000)</b>	<b>252,107,189,514</b>	<b>67,996,724,764</b>	<b>1,630,765,114,278</b>

*b, Details of the owner's equity:*

	<b>Ending balance</b>		<b>Beginning balance</b>	
	<b>Value</b>	<b>Ratio</b>	<b>Value</b>	<b>Ratio</b>
Other shareholders	1,311,056,500,000	100,00%	1,311,056,500,000	100,00%
<b>Total</b>	<b>1,311,056,500,000</b>	<b>100,00%</b>	<b>1,311,056,500,000</b>	<b>100,00%</b>

**AMERICAN VIETNAMESE BIOTECH INCORPORATION**

Address: 4th Floor, Phu Ma Duong Building, No. 85 Hoang Van Thai Street, Tan My Ward, Ho Chi Minh City, Vietnam

For the six-month period of the financial year ending 31 December 2025

**Notes to the Interim Consolidated Financial Statements (continued)***c Share*

	<u>Ending balance</u>	<u>Beginning balance</u>
Number of shares registered to issue	131,105,650	131,105,650
Number of shares issued to the public	131,105,650	131,105,650
- Ordinary shares	131,105,650	131,105,650
- Preference shares	-	-
Number of outstanding shares in circulation	131,105,650	131,105,650
- Ordinary shares	131,105,650	131,105,650
- Preference shares	-	-
An ordinary share has par value of VND 10,000./.		

**VI. ADDITIONAL INFORMATION FOR ITEMS PRESENTED IN THE INTERIM CONSOLIDATED INCOME STATEMENT****1. Revenue from sale of goods and rendering services**

	<u>Cumulative from the beginning of the year to the end of this period</u>	
	<u>Current year</u>	<u>Previous year</u>
Revenue from sale of goods and rendering services	102,051,725,225	81,408,192,173
<b>Total</b>	<b>102,051,725,225</b>	<b>81,408,192,173</b>

**2. Cost of sales**

	<u>Cumulative from the beginning of the year to the end of this period</u>	
	<u>Current year</u>	<u>Previous year</u>
Cost of goods sold and services rendered	86,256,150,530	74,949,925,060
<b>Total</b>	<b>86,256,150,530</b>	<b>74,949,925,060</b>

**3. Financial income**

	<u>Cumulative from the beginning of the year to the end of this period</u>	
	<u>Current year</u>	<u>Previous year</u>
Interest on deposits and loans	1,005,229,999	380,114,973
Gains on foreign exchanges	-	679,886,123
Gain on disposal of a subsidiary	417,962,903	-
<b>Total</b>	<b>1,423,192,902</b>	<b>1,060,001,096</b>

**4. Financial expenses**

	<u>Cumulative from the beginning of the year to the end of this period</u>	
	<u>Current year</u>	<u>Previous year</u>
Interest expense	9,244,379,475	10,016,576,291
Provision / (Reversal) of provision for investment impairment	44,664,050	27,150,345
Amortization of bond issuance costs	-	15,787,363
<b>Total</b>	<b>9,289,043,525</b>	<b>10,059,513,999</b>



**AMERICAN VIETNAMESE BIOTECH INCORPORATION**

Address: 4th Floor, Phu Ma Duong Building, No. 85 Hoang Van Thai Street, Tan My Ward, Ho Chi Minh City, Vietnam

For the six-month period of the financial year ending 31 December 2025

**Notes to the Interim Consolidated Financial Statements (continued)****5. Selling expenses**

	Cumulative from the beginning of the year to the end of this period	
	Current year	Previous year
Employee expenses	133,333,326	133,333,332
Provision expenses	-	(1,643,500,000)
Outsourced services expenses	2,080,000	17,307,375
Other monetary expenses	146,059,200	139,104,000
<b>Total</b>	<b>281,472,526</b>	<b>(1,353,755,293)</b>

**6. General and administration expenses**

	Cumulative from the beginning of the year to the end of this period	
	Current year	Previous year
Administrative employee expenses	4,509,093,379	3,305,358,966
Materials for management expenses	51,837,427	52,092,119
Office supplies expenses	184,351,336	204,587,207
Fixed asset depreciation expenses	4,403,741,162	116,643,192
Taxes, fees and charges	49,055,000	55,468,812
Provision expenses / (Reversal of provision expenses)	27,648,265,996	12,488,502,924
Outsourced service expenses	1,372,113,095	1,323,831,195
Other monetary expenses	545,078,497	256,557,570
Amortization of goodwill	28,848,328	19,848,327
<b>Total</b>	<b>38,792,384,220</b>	<b>17,822,890,312</b>

**7. Other income**

	Cumulative from the beginning of the year to the end of this period	
	Current year	Previous year
Disposal, sales of fixed assets	140,000,000	-
Contractual penalty	22,868,493	1,946,182,775
Others	241,736	114,342
<b>Total</b>	<b>163,110,229</b>	<b>1,946,297,117</b>

**8. Other expenses**

	Cumulative from the beginning of the year to the end of this period	
	Current year	Previous year
Depreciation of idle fixed assets	6,793,848,255	-
Penalties for late tax and social insurance payments	163,780,154	44,067,624
Others	96,682,675	109,616,068
<b>Total</b>	<b>7,054,311,084</b>	<b>153,683,692</b>

**AMERICAN VIETNAMESE BIOTECH INCORPORATION**

Address: 4th Floor, Phu Ma Duong Building, No. 85 Hoang Van Thai Street, Tan My Ward, Ho Chi Minh City, Vietnam

For the six-month period of the financial year ending 31 December 2025

**Notes to the Interim Consolidated Financial Statements (continued)****9. Current corporate income tax expenses**

Current corporate income tax expenses are recalculation as follows:

	Cumulative from the beginning of the year to the end of this period	
	Current year	Previous year
Total accounting profit before tax	(40,663,819,913)	(17,217,782,040)
Adjustments for accounting profit to determine corporate income tax:		
- Incremental adjustments	55,649,011,399	20,593,643,492
Depreciation of idle fixed assets	78,735,395,787	34,680,123,230
Non-deductible expenses	6,793,848,255	1,945,830,565
Penalties for late payment of taxes and insurance	11,084,274	-
Loss from associates upon consolidation	248,857,316	44,067,624
Amortization of goodwill	2,628,486,384	19,848,327
Losses of subsidiaries under separate financial statements	28,848,328	14,656
- Reduction adjustments	69,024,271,230	32,670,362,058
Gain on disposal of a subsidiary	(23,086,384,388)	(14,086,479,738)
Effect of provision for impairment of investments in subsidiaries upon consolidation	(417,962,903)	-
Taxable income	(22,668,421,485)	(14,086,479,738)
Tax-exempt income	14,985,191,486	3,375,861,452
Losses carried forward from previous years	-	(1,229,475,964)
Taxable profit	(13,273,808,416)	-
Corporate income tax rate	1,711,383,070	2,146,385,488
Corporate income tax payable at the statutory tax rate	20%	20%
Corporate income tax payable	342,276,614	429,277,098
Corporate income tax payable	342,276,614	429,277,098
Total current corporate income tax expense	342,276,614	429,277,098

**10. Basic/diluted earnings per share**

	Cumulative from the beginning of the year to the end of this period	
	Current year	Previous year
Accounting profit after corporate income tax	(39,721,984,252)	(16,730,798,237)
Adjustments to increase or decrease accounting profit to determine the profit allocated to shareholders holding common shares:		
Profit used to calculate basic earnings per share	-	-
Weighted average number of common shares outstanding during the period	(39,721,984,252)	(16,730,798,237)
Basic/diluted earnings per share	131,105,650	131,105,650
	(303)	(128)



**AMERICAN VIETNAMESE BIOTECH INCORPORATION**

Address: 4th Floor, Phu Ma Duong Building, No. 85 Hoang Van Thai Street, Tan My Ward, Ho Chi Minh City, Vietnam

For the six-month period of the financial year ending 31 December 2025

**Notes to the Interim Consolidated Financial Statements (continued)**

Average outstanding common shares during the year are identified as follows:

	<b>Current year</b>	<b>Previous year</b>
Average number of outstanding common shares at the beginning of the period	131,105,650	131,105,650
Impact of treasury share sales	-	-
Impact of issuance of additional ordinary shares during the period	-	-
<b>Average number of outstanding common shares during the period</b>	<b>131,105,650</b>	<b>131,105,650</b>

**11. Cost by factors**

	<b>Cumulative from the beginning of the year to the end of this period</b>	
	<b>Current year</b>	<b>Previous year</b>
Raw material cost	609,623,626	393,637,103
Labor cost	6,863,428,541	4,334,092,171
Fixed asset depreciation cost	16,880,083,914	10,660,383,426
Taxes, fees and charges	49,055,000	55,468,812
Provision expenses	27,648,265,996	10,845,002,924
Outsourced service expenses	1,111,184,603	1,737,012,055
Other monetary expenses	1,040,402,128	424,019,807
<b>Total</b>	<b>54,202,043,808</b>	<b>28,449,616,298</b>

**VII. OTHER INFORMATION****1. Information about related parties**

Stakeholders of the Enterprise include: key management members, individuals related to key management members and other stakeholders.

**A, Transactions and balances with key management members and individuals related to key management members**

Key management members include: members of the Board of Directors and members of the Executive Board (Board of Directors, Chief Accountant). Individuals related to key management members are close family members of key management members.

*Key Management Members' Compensation:*

	<b>Current year</b>	<b>Previous year</b>
Mrs. Dang Nhi Nuong	121,000,000	121,000,000

*During the period, the unit did not have any transactions with related parties.*

**B, Transactions with other related parties**

Other related parties to the Enterprise include: subsidiaries, affiliated companies, individuals with direct or indirect voting rights in the Enterprise and close members of their families, enterprises managed by key management personnel and individuals with direct or indirect voting rights of the Enterprise and close members of their families.

**Related parties include:**

	<b>Relationship</b>
Associates as listed in Note V.13a	Associate
Mr. Dang Vu Toan	Director of subsidiary
Mr. Pham Van Su	Director of subsidiary
Ms. Bui Thi Phuong Thao	Director of subsidiary
Mr. Vu Hoang Chuong	Director of subsidiary
Mr. Nguyen Hong Thanh	Director of subsidiary

**AMERICAN VIETNAMESE BIOTECH INCORPORATION**

Address: 4th Floor, Phu Ma Duong Building, No. 85 Hoang Van Thai Street, Tan My Ward, Ho Chi Minh City, Vietnam

For the six-month period of the financial year ending 31 December 2025

**Notes to the Interim Consolidated Financial Statements (continued)***Transactions with other related parties*

The main transactions arising during the period between the Company and other related parties are as follows:

	<b>Cumulative from the beginning of the year to the end of this period</b>	
	<b>Current year</b>	<b>Previous year</b>
<b>Golab Phap Van Diagnostic Center Joint Stock Company</b>		
Capital support receivables	-	2,500,000,000
<b>Famicare Phap Van Joint Stock Company</b>		
Capital support receivables	-	2,500,000,000
<b>Mr Pham Van Su</b>		
Loan payables	-	3,500,00,000
Loan repayment	-	3,500,00,000
<b>Mr Vu Hoang Chuong</b>		
Loan payables	-	290,000,000
Loan repayment	1,820,000,000	-
<b>Mrs Bui Thi Phuong Thao</b>		
Loan repayment	1,680,000,000	-
<b>Mr Nguyen Hong Thanh</b>		
Loan payables	46,991,222	-
<b>Mr Dang Vu Toan</b>		
Collection of interest from capital support	1,000,000,000	-
<b>Golab Binh Duong Diagnostic Center Joint Stock Company</b>		
Collection of interest from capital support	500,000,000	-
<b>Golab Tan An Diagnostic Center Joint Stock Company (Long An)</b>		
Collection of interest from capital support	1,750,000,000	-
<b>Golab Ca Mau Test Center Joint Stock Company</b>		
Loan receivables	1,138,000,000	-
<b>Famicare Hung Yen Joint Stock Company</b>		
Collection of capital support	3,500,000,000	-
Interest receivables from capital support	79,465,822	-
Collection of interest from capital support	79,465,822	-
Receivables from investment capital contribution	-	10,500,000,000
<b>During The Period, The Company Contributed Capital To Associates As Follows:</b>		
Golab Ben Tre Test Center Joint Stock Company	7,330,000,000	-
Golab Binh Thuan Test Center Joint Stock Company	6,876,000,000	-
Golab Yen Bai Test Center Joint Stock Company	7,388,000,000	-



**AMERICAN VIETNAMESE BIOTECH INCORPORATION**

Address: 4th Floor, Phu Ma Duong Building, No. 85 Hoang Van Thai Street, Tan My Ward, Ho Chi Minh City, Vietnam

For the six-month period of the financial year ending 31 December 2025

**Notes to the Interim Consolidated Financial Statements (continued)**

	<b>Cumulative from the beginning of the year to the end of this period</b>	
	<b>Current year</b>	<b>Previous year</b>
Golab Cao Bang Test Center Joint Stock Company	6,054,000,000	-
Golab Thai Binh Test Center Joint Stock Company	4,337,000,000	-
Golab Vinh Yen Diagnostic Center Joint Stock Company	450,000,000	-
Golab Bac Giang Test Center Joint Stock Company	7,384,000,000	-
Golab Lang Son Test Center Joint Stock Company	4,400,000,000	-
Golab Quang Tri Diagnostic Center Joint Stock Company	1,350,000,000	-
Golab Dien Bien Test Center Joint Stock Company	14,400,000,000	-
Golab Dak Nong Test Center Joint Stock Company	9,130,000,000	-
Golab Son La Test Center Joint Stock Company	8,862,000,000	-
Golab Ca Mau Test Center Joint Stock Company	14,700,000,000	-
Famicare Nam Dinh Joint Stock Company	4,900,000,000	-
Famicare Ca Mau Joint Stock Company	4,900,000,000	-
Famicare Son La Joint Stock Company	2,612,500,000	-
Golab Hue Test Center Joint Stock Company	1,200,000,000	-
Golab Binh Thuan Test Center Joint Stock Company	2,700,000,000	-
Famicare Quang Nam Joint Stock Company	4,783,000,000	-
Golab Binh Phuoc Test Center Joint Stock Company	421,000,000	-
Huu Nghi Medicare Clinic Joint Stock Company	-	1,763,500,000
Golab Ninh Binh Test Center Joint Stock Company	-	1,000,000,000
Golab Phap Van Diagnostic Center Joint Stock Company	-	10,500,000,000
Famicare Phap Van Joint Stock Company	-	10,500,000,000
Golab Go Vap Diagnostic Center Joint Stock Company	-	10,500,000,000
Nghe An Polyclinic Joint Stock Company	-	1,000,000,000

**The Company's transactions of sales and service provision with related parties during the period are as follows:**

	<b>Revenue</b>	<b>Accounts receivable</b>	<b>Cash collected</b>
Ba Dinh Polyclinic Joint Stock Company	1,975,000,000	2,073,750,000	-
Huu Nghi Medicare Clinic Joint Stock Company	-	2,400,330,000	2,400,330,000
Golab Ninh Binh Test Center Joint Stock Company	35,000,000	2,438,830,000	2,400,330,000
Nghe An Polyclinic Joint Stock Company	35,000,000	6,239,160,000	5,363,330,000
Golab An Giang Diagnostic Center Joint Stock Company	-	3,800,330,000	3,800,330,000
Golab Bac Giang Test Center Joint Stock Company	260,000,000	273,000,000	273,000,000
Golab Bac Kan Test Center Joint Stock Company	260,000,000	273,000,000	273,000,000
Golab Bac Lieu Diagnostic Center Joint Stock Company	-	5,600,660,000	680,000,000
Golab Bac Ninh Diagnostic Center Joint Stock Company	-	2,625,000,000	2,625,000,000
Golab Ben Tre Test Center Joint Stock Company	2,120,000,000	2,226,000,000	2,033,000,000
Golab Bien Hoa Diagnostic Center Joint Stock Company	35,000,000	5,639,160,000	-
Golab Binh Dinh Diagnostic Center Joint Stock Company	260,000,000	273,000,000	273,000,000

**AMERICAN VIETNAMESE BIOTECH INCORPORATION**

Address: 4th Floor, Phu Ma Duong Building, No. 85 Hoang Van Thai Street, Tan My Ward, Ho Chi Minh City, Vietnam

For the six-month period of the financial year ending 31 December 2025

**Notes to the Interim Consolidated Financial Statements (continued)**

Golab Binh Phuoc Test Center Joint Stock Company	2,120,000,000	2,226,000,000	-
Golab Binh Thuan Test Center Joint Stock Company	4,095,000,000	4,299,750,000	2,226,000,000
Golab Cao Bang Test Center Joint Stock Company	2,395,000,000	2,514,750,000	-
Golab Da Nang Diagnostic Center Joint Stock Company	-	10,085,770,000	7,685,330,000
Golab Dak Lak Diagnostic Center Joint Stock Company	260,000,000	273,000,000	273,000,000
Golab Dak Nong Test Center Joint Stock Company	260,000,000	273,000,000	-
Golab Dien Bien Test Center Joint Stock Company	260,000,000	273,000,000	273,000,000
Golab Gia Lai Diagnostic Center Joint Stock Company	-	3,885,000,000	3,885,000,000
Golab Go Vap Diagnostic Center Joint Stock Company	-	5,600,660,000	1,885,000,000
Golab Ha Giang Diagnostic Center Joint Stock Company	260,000,000	273,000,000	-
Golab Ha Tinh Diagnostic Center Joint Stock Company	-	2,400,330,000	2,400,330,000
Golab Hai Duong Diagnostic Center Joint Stock Company	-	2,625,000,000	1,685,000,000
Golab Hue Test Center Joint Stock Company	2,250,000,000	2,362,500,000	-
Golab Khanh Hoa Test Center Joint Stock Company	2,235,000,000	2,346,750,000	273,000,000
Golab Kien Giang Diagnostic Center Joint Stock Company	-	2,782,500,000	2,782,500,000
Golab Kon Tum Diagnostic Center Joint Stock Company	-	1,800,330,000	-
Golab Lam Dong Test Center Joint Stock Company	4,095,000,000	4,299,750,000	-
Golab Lang Son Test Center Joint Stock Company	260,000,000	273,000,000	273,000,000
Golab Nam Dinh Test Center Joint Stock Company	260,000,000	273,000,000	-
Golab Ninh Thuan Test Center Joint Stock Company	260,000,000	273,000,000	-
Golab Phap Van Diagnostic Center Joint Stock Company	35,000,000	7,159,160,000	7,120,660,000
Golab Quang Binh Diagnostic Center Joint Stock Company	-	4,630,330,000	4,630,330,000
Golab Quang Nam Test Center Joint Stock Company	260,000,000	273,000,000	-
Golab Quang Ngai Diagnostic Center Joint Stock Company	-	1,800,330,000	-
Golab Quang Tri Diagnostic Center Joint Stock Company	260,000,000	2,673,440,000	753,000,000
Golab Son La Test Center Joint Stock Company	260,000,000	273,000,000	174,000,000
Golab Tay Ninh Diagnostic Center Joint Stock Company	-	6,978,320,000	6,978,320,000
Golab Thai Binh Test Center Joint Stock	260,000,000	273,000,000	173,000,000



**AMERICAN VIETNAMESE BIOTECH INCORPORATION**

Address: 4th Floor, Phu Ma Duong Building, No. 85 Hoang Van Thai Street, Tan My Ward, Ho Chi Minh City, Vietnam

For the six-month period of the financial year ending 31 December 2025

**Notes to the Interim Consolidated Financial Statements (continued)**

Company			
Golab Thai Nguyen Test Center Joint Stock Company	275,000,000	288,750,000	-
Golab Thanh Hoa Test Center Joint Stock Company	260,000,000	273,000,000	-
Golab Tien Giang Diagnostic Center Joint Stock Company	-	5,600,660,000	-
Golab Tra Vinh Diagnostic Center Joint Stock Company	-	2,400,330,000	2,400,330,000
Golab Tuyen Quang Diagnostic Center Joint Stock Company	-	5,600,660,000	5,554,000,000
Golab Vinh Phuc Diagnostic Center Joint Stock Company	-	1,800,330,000	1,800,330,000
Golab Vinh Yen Diagnostic Center Joint Stock Company	260,000,000	273,000,000	273,000,000
Golab Yen Bai Test Center Joint Stock Company	2,395,000,000	2,514,750,000	-

As at the end of the accounting period, related party balances are presented in detail in Notes V.5, V.13 and V.18./.

**2. Fair value of financial assets and liabilities**

	Book value		Fair value	
	Ending balance	Beginning Balance	Ending balance	Beginning Balance
<b>Financial assets</b>				
Cash and cash equivalents	13,152,760,376	16,194,180,757	13,152,760,376	16,194,180,757
Held to maturity investments	98,300,000	98,300,000	98,300,000	98,300,000
Trade receivables	140,771,493,906	296,680,554,862	140,771,493,906	296,680,554,862
Loan receivables	70,808,050,000	62,850,000,000	70,808,050,000	62,850,000,000
Other receivables	499,782,546,265	66,926,740,977	499,782,546,265	66,926,740,977
Financial assets available for sale	734,938,191,325	684,683,841,759	734,938,191,325	684,683,841,759
<b>Total</b>	<b>1,459,551,341,872</b>	<b>1,127,433,618,355</b>	<b>1,459,551,341,872</b>	<b>1,127,433,618,355</b>
<b>Financial liabilities</b>				
Loans and Debts	149,673,087,049	154,625,095,827	149,673,087,049	154,625,095,827
Payable to seller	25,279,812,907	15,246,276,978	25,279,812,907	15,246,276,978
Other payables	108,335,940,769	109,870,915,333	108,335,940,769	109,870,915,333
<b>Total</b>	<b>283,288,840,725</b>	<b>279,742,288,138</b>	<b>283,288,840,725</b>	<b>279,742,288,138</b>

The fair value of financial assets and financial liabilities is reflected at the amount at which the financial instruments could be exchanged in a current transaction between knowledgeable and willing parties.

The Company uses the following methods and assumptions to estimate fair value:

- The fair value of cash and cash equivalents, trade receivables, loans, other receivables, borrowings, trade payables and other short-term payables is equivalent to the book value (net of provisions for estimated uncollectibility) of these items due to their short maturity.
- The fair value of loans, trade receivables, other receivables, borrowings, trade payables and other long-term payables, held-to-maturity investments that are not listed on the stock market and do not

**AMERICAN VIETNAMESE BIOTECH INCORPORATION**

Address: 4th Floor, Phu Ma Duong Building, No. 85 Hoang Van Thai Street, Tan My Ward, Ho Chi Minh City, Vietnam

For the six-month period of the financial year ending 31 December 2025

**Notes to the Interim Consolidated Financial Statements (continued)**

have a trading price announced by 3 securities companies is estimated by discounting cash flows at the interest rate applicable to debts with similar characteristics and remaining maturity.

**3. Credit risk**

Credit risk is the risk that a party to a contract will not be able to perform its obligations resulting in financial loss to the Company.

The Company is exposed to credit risk from its operating activities (primarily trade receivables) and financing activities (bank deposits, loans and other financial instruments).

**Accounts receivable**

The Company minimizes credit risk by only dealing with financially sound entities, requiring letters of credit to be opened for entities that are trading for the first time or have no information on their financial capabilities, and having accounts receivable staff regularly monitor receivables to urge collection. On this basis, and the Company's receivables are related to many different customers, credit risk is not concentrated on a particular customer.

**Deposits**

Most of the bank deposits of the company is deposited in large, reputable banks in Vietnam. The company finds that the level of concentration of credit risk for bank deposits is low.

**4. Risk liquidity risk**

Liquidity risk is the risk The company had difficulty meeting its financial obligations due to lack of funds.

The Board of Directors has ultimate responsibility for liquidity risk management. The Company's liquidity risk arises primarily from the mismatch of maturities between its financial assets and financial liabilities.

The Company manages liquidity risk by maintaining an appropriate level of cash and cash equivalents and borrowings at levels deemed necessary by the Board. The leadership considers it sufficient to meet the operational needs of the company aims to minimize the impact of cash flow fluctuations.

The maturity of financial liabilities based on undiscounted contractual payments is as follows:

	1 year or less	Over 1 year to 5 years	Over 5 years	Total
<b>Ending balance</b>				
Loans and Debts	149,673,087,049	-	-	149,673,087,049
Payable to seller	25,279,812,907	-	-	25,279,812,907
Other payables	107,998,142,486	337,798,283	-	108,335,940,769
<b>Total</b>	<b>282,951,042,442</b>	<b>337,798,283</b>	<b>-</b>	<b>283,288,840,725</b>
<b>Beginning Balance</b>				
Loans and Debts	28,125,095,827	126,500,000,000	-	154,625,095,827
Payable to seller	15,246,276,978	-	-	15,246,276,978
Other payables	109,533,117,050	337,798,283	-	109,870,915,333
<b>Total</b>	<b>152,904,489,855</b>	<b>126,837,798,283</b>	<b>-</b>	<b>279,742,288,138</b>

The Company believes that the concentration of risk with respect to debt repayment is low. The Company is able to repay its debts when they fall due from cash flows from operations and proceeds from maturing financial assets.



## **AMERICAN VIETNAMESE BIOTECH INCORPORATION**

Address: 4th Floor, Phu Ma Duong Building, No. 85 Hoang Van Thai Street, Tan My Ward, Ho Chi Minh City, Vietnam

For the six-month period of the financial year ending 31 December 2025

### **Notes to the Interim Consolidated Financial Statements (continued)**

---

#### **5. Market risk**

Market risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market prices. Market risk includes three types: currency risk, interest rate risk and other price risk.

The sensitivity analyses presented below are based on a constant value of net debt, with the ratio of fixed-rate debt to floating-rate debt remaining constant.

##### ***Foreign exchange risk***

Currency risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in foreign exchange rates.

##### ***Interest rate risk***

Interest rate risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rates.

Interest rate risk of Company mainly related to money and loans.

The Company manages interest rate risk by analyzing market conditions to obtain the most favorable interest rates while remaining within its risk management limits.

##### ***Other price risks***

Other price risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market prices other than changes in interest rates and foreign exchange rates.

#### **6. Significant events during the accounting period affecting the financial statements**

- American VietNameese Biotech INC ("AMV") with many years of experience in the medical field: providing machinery and equipment systems, supplying consumables,... Facing the increasing demand for health care services, cancer screening and home health care, learning from the infusion center model - built and operated according to Japan's international safety standards - specializing in providing drug, vitamin, protein, therapy and water infusion services to improve patient health, is gradually becoming a popular trend in many countries such as Japan, the US, Thailand. However, in Vietnam, this model is still quite new and has not been widely deployed. At the same time, after reviewing and evaluating the overall mobile examination vehicle project, investment project, joint venture linking medical image archiving and transmission systems (PACS system) with hospitals that the company previously pursued, it did not meet expectations as expected. Therefore, the company boldly divested all or part of those projects, the Company has determined a strategy to strongly develop the clinic and infusion center model in the coming time. This business strategy was approved at the 2024 Annual General Meeting of Shareholders. At present, the Company is continuing to carry out the necessary procedures to put into operation a chain of clinics across 34 provinces and cities nationwide, with the expectation of providing early and reliable diagnostic testing at the most cost-effective level through its network of testing centers.

- Resolution of the Board of Directors No. 0601/2025/NQ-HĐQT dated January 6, 2025 and Resolution of the Board of Directors No. 1701/2025/NQ-HĐQT dated January 17, 2025 on receiving the transfer of VND 204,227,000,000 of contributed capital at Phu Tho Provincial General Hospital, from Sara Vietnam Joint Stock Company. The transfer value from Sara Vietnam Joint Stock Company under contract No. 01/2025/HĐCN/SARA-VIETMY dated February 15, 2025 is VND 204,227,000,000. Up to now, the Company has paid the entire amount of VND 204,227,000,000. However, according to Resolution of the Board of Directors No. 1604/2025/NQ-HĐQT dated April 16, 2025, the Company decided to withdraw capital early from Phu Tho Provincial General Hospital, the capital withdrawal plan is from 2025 to 2028. Up to now, the Hospital has transferred 17,5 billion to the company.

**AMERICAN VIETNAMESE BIOTECH INCORPORATION**

Address: 4th Floor, Phu Ma Duong Building, No. 85 Hoang Van Thai Street, Tan My Ward, Ho Chi Minh City, Vietnam

For the six-month period of the financial year ending 31 December 2025

**Notes to the Interim Consolidated Financial Statements (continued)**

**7. Comparison information**

The comparative figures in the interim consolidated balance sheet are those from the consolidated balance sheet as at December 31, 2024, which were audited by Nhan Tam Viet Auditing Company Limited.

The comparative figures in the interim consolidated statement of profit or loss and the interim consolidated statement of cash flows are those from the interim consolidated statement of profit or loss and the interim consolidated statement of cash flows for the first six months of the financial year ended December 31, 2024, which were reviewed by Nhan Tam Viet Auditing Company Limited.

Prepared on 28 August 2025

Prepared by



**Nguyen Thu Huyen**

Chief Accountant



**Dang Thi Thanh Tuyen**

Director



**Dang Nhi Nuong**